MRC Centre for Transplantation
Lead Research Organisation:
King's College London
Department Name: Transplantation Immunology & Mucosal Bio
Abstract
Organ transplantation has saved the lives of many thousands of people, but transplants still don't last as long as they should. In addition, to prevent rejection, high doses of toxic drugs are used to dampen the immune response. These can not only harm the transplant, but can have lethal side effects on the recipient.
Since it started in October 2007, the Centre has made significant progress towards improving the health of people who need transplants. We have devised ways to make their transplanted organ survive longer. This includes the development of engineered proteins which, when planted in donor kidneys, reduce inflammation and blood clot formation after transplantation. In addition, we have pioneered less harmful, more natural methods to coax the immune system into accepting the transplant, using cells taken from the patient. Remarkably, as a result of monitoring the immune system, we are close to being able to judge which patients can stop taking conventional therapy without rejecting the graft. At the same time, we are developing advanced scanning techniques that will enable physicians to diagnose whether a transplant is inflamed and to offer appropriate treatment.
As we approach the next five years of development, we shall conduct clinical trials to establish whether these innovations can benefit healthcare as the basic research has promised. Potential benefits include extending the life of the transplant and offering transplantation to more of those in need. We are also supporting new branches of science that make success more likely.
Advances of this complexity are made possible by bringing together a large workforce of scientists, clinicians and technologists under the same roof. The MRC Centre for Transplantation has created this capability within the UK. It collaborates with the Centre for Medical Law and Ethics at King's College to ensure a high standard of communication and public engagement regarding the regulation and ethics of transplant research. A programme of special events and media coverage will help keep the public and patients informed during innovation. Health economists are also to be part of the Centre to provide the opportunity to make more accurate forecasts about the costs and potential benefits of our research.
Future success will depend on recruiting and training the brightest minds to deliver this work through the next 5-10 years of development and ensure the research is translated into social and economic benefit.
Since it started in October 2007, the Centre has made significant progress towards improving the health of people who need transplants. We have devised ways to make their transplanted organ survive longer. This includes the development of engineered proteins which, when planted in donor kidneys, reduce inflammation and blood clot formation after transplantation. In addition, we have pioneered less harmful, more natural methods to coax the immune system into accepting the transplant, using cells taken from the patient. Remarkably, as a result of monitoring the immune system, we are close to being able to judge which patients can stop taking conventional therapy without rejecting the graft. At the same time, we are developing advanced scanning techniques that will enable physicians to diagnose whether a transplant is inflamed and to offer appropriate treatment.
As we approach the next five years of development, we shall conduct clinical trials to establish whether these innovations can benefit healthcare as the basic research has promised. Potential benefits include extending the life of the transplant and offering transplantation to more of those in need. We are also supporting new branches of science that make success more likely.
Advances of this complexity are made possible by bringing together a large workforce of scientists, clinicians and technologists under the same roof. The MRC Centre for Transplantation has created this capability within the UK. It collaborates with the Centre for Medical Law and Ethics at King's College to ensure a high standard of communication and public engagement regarding the regulation and ethics of transplant research. A programme of special events and media coverage will help keep the public and patients informed during innovation. Health economists are also to be part of the Centre to provide the opportunity to make more accurate forecasts about the costs and potential benefits of our research.
Future success will depend on recruiting and training the brightest minds to deliver this work through the next 5-10 years of development and ensure the research is translated into social and economic benefit.
Technical Summary
In 2007, the Centre set out to convert its extensive knowledge of inflammation, immunity and tolerance into new treatment, diagnostic and prognostic technologies for the benefit of patients. Our priorities were to overcome the initial barriers to transplantation presented by the immune system and to induce tolerance in patients with guidance from immune prediction and monitoring, so reducing some of the major limitations of modern transplantation.
To do this, we created links with protein and cell therapeutics, imaging sciences and genetics, and between clinical specialities responsible for the treatment of patients with diabetes, liver, kidney, bone marrow and dental diseases. As a result, the first membrane-targeted therapeutic regulators are about to enter a multicentre efficacy trial; the cell therapy strategy has progressed to become part of several investigational protocols designed to induce tolerance; markers of tolerance are undergoing extensive evaluation in man; and new imaging ligands that detect activated complement fragments and migratory T cells have emerged. A teaching framework built around these goals is equipping trainees to engage in multidisciplinary research. A programme of patient and public involvement promotes awareness of the importance of science in transplant medicine and ensures we are responsive to their expectations.
Our plan is to regroup the expanded number of basic and clinical research programmes into fewer themes which reflect areas of strategic value. This includes islet and hepatocyte transplantation, where inadequate long-term outcomes are likely to benefit from the specific expertise of the Centre. In support, an expanded training scheme will develop leadership skills in the distinct areas defined by the new themes, i.e. protein and cell engineering, immune monitoring, imaging and informatics. A parallel theme to improve methods of health economic assessment for early research is designed to support these goals.
To do this, we created links with protein and cell therapeutics, imaging sciences and genetics, and between clinical specialities responsible for the treatment of patients with diabetes, liver, kidney, bone marrow and dental diseases. As a result, the first membrane-targeted therapeutic regulators are about to enter a multicentre efficacy trial; the cell therapy strategy has progressed to become part of several investigational protocols designed to induce tolerance; markers of tolerance are undergoing extensive evaluation in man; and new imaging ligands that detect activated complement fragments and migratory T cells have emerged. A teaching framework built around these goals is equipping trainees to engage in multidisciplinary research. A programme of patient and public involvement promotes awareness of the importance of science in transplant medicine and ensures we are responsive to their expectations.
Our plan is to regroup the expanded number of basic and clinical research programmes into fewer themes which reflect areas of strategic value. This includes islet and hepatocyte transplantation, where inadequate long-term outcomes are likely to benefit from the specific expertise of the Centre. In support, an expanded training scheme will develop leadership skills in the distinct areas defined by the new themes, i.e. protein and cell engineering, immune monitoring, imaging and informatics. A parallel theme to improve methods of health economic assessment for early research is designed to support these goals.
Planned Impact
Benefit to patients
Improved quality of life, graft and patient survival rates, fewer interventions including less use of drug and dialysis treatment:
- Painting the donor organ with protective treatment that reduces inflammation and increases the lifespan of the transplant
- Having to take fewer drugs with unpleasant or dangerous side effects achieved with regimens using cell therapies in place of conventional treatment with broad-acting drugs
- Better patient stratification with new biomarkers and immune monitoring, allowing reduced drug usage where immune tolerance has developed
- Shorter wait for a kidney transplant through more donor organs being available with the application of organ-painting
- Evidence should be visible within 5-10 years
Benefits to the NHS
Cost/resource/efficiency benefits gained through costs of treatment (drug and dialysis costs) and patient and graft outcomes:
- Lower dialysis costs by enabling more transplants to be carried out with the use of organ painting and by fewer patients having to return to dialysis after transplantation
- Lower cost of dialysis in the early post transplant period due to more rapid recovery of painted donor organs
- Lower maintenance drug costs by keeping patients on fewer drugs where immune tolerance can be detected and/or can be induced by cell therapy
- Increased patient and graft survival rates with wider application of these treatment and diagnostic technologies, within 10 years
Benefits to the Economy
Exploitation of IP to form new products which contribute to UK economy and allow return on public investment in the work of the MRC Centre/KCL, by:
- New intellectual property based around these therapeutic and biomarker technologies (interest already showing in new cytotopic products and biomarkers of tolerance)
- Healthcare savings since maintenance on a transplant is more cost-effective than dialysis.
Benefits to Wider Society
Engagement/participation, leading to:
- Public confidence in organ donation, building on our ability to engage the public and influence policy on matters that include research in transplantation
- Influence willingness to participate in organ donations schemes by appreciating the scientific commitment though research
Improved quality of life, graft and patient survival rates, fewer interventions including less use of drug and dialysis treatment:
- Painting the donor organ with protective treatment that reduces inflammation and increases the lifespan of the transplant
- Having to take fewer drugs with unpleasant or dangerous side effects achieved with regimens using cell therapies in place of conventional treatment with broad-acting drugs
- Better patient stratification with new biomarkers and immune monitoring, allowing reduced drug usage where immune tolerance has developed
- Shorter wait for a kidney transplant through more donor organs being available with the application of organ-painting
- Evidence should be visible within 5-10 years
Benefits to the NHS
Cost/resource/efficiency benefits gained through costs of treatment (drug and dialysis costs) and patient and graft outcomes:
- Lower dialysis costs by enabling more transplants to be carried out with the use of organ painting and by fewer patients having to return to dialysis after transplantation
- Lower cost of dialysis in the early post transplant period due to more rapid recovery of painted donor organs
- Lower maintenance drug costs by keeping patients on fewer drugs where immune tolerance can be detected and/or can be induced by cell therapy
- Increased patient and graft survival rates with wider application of these treatment and diagnostic technologies, within 10 years
Benefits to the Economy
Exploitation of IP to form new products which contribute to UK economy and allow return on public investment in the work of the MRC Centre/KCL, by:
- New intellectual property based around these therapeutic and biomarker technologies (interest already showing in new cytotopic products and biomarkers of tolerance)
- Healthcare savings since maintenance on a transplant is more cost-effective than dialysis.
Benefits to Wider Society
Engagement/participation, leading to:
- Public confidence in organ donation, building on our ability to engage the public and influence policy on matters that include research in transplantation
- Influence willingness to participate in organ donations schemes by appreciating the scientific commitment though research
Organisations
- King's College London (Lead Research Organisation)
- European Cooperation in Science and Technology (COST) (Collaboration)
- Zhejiang University (Collaboration)
- Catalan Health Institute (ICS) (Collaboration)
- Roslin Biocentre Ltd (Collaboration)
- University of Colorado Denver (Collaboration)
- August Pi i Sunyer Biomedical Research Institute (Collaboration)
- Queen Alexandra Hospital (Collaboration)
- ChemoCentryx (Collaboration)
- EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST (Collaboration)
- University Hospital of Nantes (Collaboration)
- ALTA (Collaboration)
- University Libre Bruxelles (Université Libre de Bruxelles ULB) (Collaboration)
- Cellogic GmbH (Collaboration)
- University of Hong Kong (Collaboration)
- University of Pittsburgh (Collaboration)
- Alexion Pharmaceuticals (Collaboration)
- Royal Free Hospital (Collaboration)
- Academic Medical Center (Collaboration)
- University of Mons (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- Novartis (Collaboration)
- Newcastle University (Collaboration)
- UCB Pharma (Collaboration)
- University of East Anglia (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Chelsea Therapeutics (Collaboration)
- Queen Elizabeth Hospital Birmingham (Collaboration)
- Hannover Medical School (Collaboration)
- Ingenza Ltd (Collaboration)
- Universität Hamburg (Collaboration)
- University Hospitals Leuven (Collaboration)
- Great Ormond Street Hospital (GOSH) (Collaboration)
- Emory University (Collaboration)
- Immunotech S.A.S. (Collaboration)
- Royal Free London NHS Foundation Trust (Collaboration)
- Immune Tolerance Network (Collaboration)
- University Hospital La Paz (Collaboration)
- SALFORD ROYAL NHS FOUNDATION TRUST (Collaboration)
- Leibniz Institute for Interactive Materials (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- European Commission (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- King's College Hospital NHS Foundation Trust (NCH) (Collaboration)
- University of Regensburg (Collaboration)
- Leeds Teaching Hospitals NHS Trust (Collaboration)
- Utrecht University (Collaboration)
- Apollo Therapeutics (Collaboration)
- Brussels Saint-Luc University Hospital (UCL) (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Guy's and St Thomas' NHS Foundation Trust (Collaboration)
- Hull and East Yorkshire Hospitals NHS Trust (Collaboration)
- Swiss Center for Electronics and Microtechnology (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- Charité Campus Virchow - Hospital (Collaboration)
- Charité - University of Medicine Berlin (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (Collaboration)
- TcLand Expression (Collaboration)
- Genome Identification Diagnostics GmbH (Collaboration)
- St George's Healthcare NHS Trust (Collaboration)
- Xi'an Jiaotong University (Collaboration)
- Beth Israel Deaconess Medical Center (Collaboration)
- Leicester General Hospital (Collaboration)
- Université Catholique de Louvain (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Astellas Pharma (Collaboration)
- Milenia Biotec GmbH (Collaboration)
- Institute for Clinical and Experimental Medicine (IKEM) (Collaboration)
- Duke University (Collaboration)
- City of Guangzhou (Collaboration)
- NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- British Association of Urological Surgeons (Collaboration)
- University of Dresden (Collaboration)
- CARDIFF AND VALE UNIVERSITY HEALTH BOARD (Collaboration)
- Sheffield Teaching Hospitals NHS Foundation Trust (Collaboration)
Publications
Dhaliwal B
(2013)
Conformational plasticity at the IgE-binding site of the B-cell receptor CD23.
in Molecular immunology
Knight J
(2012)
Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis
in Human Molecular Genetics
Lay E
(2015)
Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitro.
in Clinical and experimental immunology
Hess C
(2016)
Complement-Mediated Regulation of Metabolism and Basic Cellular Processes.
in Immunity
Montero RM
(2016)
Complement-here, there and everywhere, but what about the transplanted organ?
in Seminars in immunology
Kolev M
(2014)
Complement--tapping into new sites and effector systems.
in Nature reviews. Immunology
Sacks S
(2013)
Complement Therapeutics
Kolev M
(2015)
Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses.
in Immunity
Nauser CL
(2017)
Complement Recognition Pathways in Renal Transplantation.
in Journal of the American Society of Nephrology : JASN
Kemper C
(2014)
Complement nomenclature 2014.
in Molecular immunology
Yiu WH
(2018)
Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy.
in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
West E
(2019)
Complement and T Cell Metabolism: Food for Thought
in Immunometabolism
Yamamoto H
(2014)
Complement and IL-22: partnering up for border patrol.
in Immunity
West EE
(2020)
Complement and human T cell metabolism: Location, location, location.
in Immunological reviews
Popat RJ
(2014)
Complement and glomerular diseases.
in Nephron. Clinical practice
Afzali B
(2013)
Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation.
in Clinical journal of the American Society of Nephrology : CJASN
Dolton G
(2014)
Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.
in Clinical and experimental immunology
Twist K
(2013)
Comparison of Depressive Symptoms in Type 2 Diabetes Using a Two-Stage Survey Design
in Psychosomatic Medicine
Fonseka T
(2015)
Comparing robotic, laparoscopic and open cystectomy: a systematic review and meta-analysis.
in Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
Ermini L
(2012)
Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.
in Molecular immunology
Combadière C
(2013)
Comment on "Ccl2, Cx3cr1 and Ccl2/Cx3cr1 chemokine deficiencies are not sufficient to cause age-related retinal degeneration" by Luhmann et al. (Exp. Eye Res. 2013; 107: 80.doi: 10.1016).
in Experimental eye research
Shafti A
(2015)
Comfort and learnability assessment of a new soft robotic manipulator for minimally invasive surgery.
in Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Hussain T
(2015)
Combined coronary lumen and vessel wall magnetic resonance imaging with i-T2prep: influence of nitroglycerin.
in The international journal of cardiovascular imaging
Wu W
(2018)
Collectin-11 Promotes the Development of Renal Tubulointerstitial Fibrosis.
in Journal of the American Society of Nephrology : JASN
Dong X
(2017)
Collectin-11 Is an Important Modulator of Retinal Pigment Epithelial Cell Phagocytosis and Cytokine Production.
in Journal of innate immunity
| Title | 3D prostates |
| Description | 3D printed prostates |
| Type Of Art | Image |
| Year Produced | 2015 |
| Impact | Developed in collaboration with Nuada Medical for patient counselling and surgical planning during robotic procedures |
| Title | Translucent |
| Description | Tablet guided surgery |
| Type Of Art | Image |
| Year Produced | 2014 |
| Impact | Developed a tablet based tool and performed the first in man for surgical navigation in UK and Italy. Demonstrated at the World Robotic Surgery Event with KCL being the only selected University from UK amongst 12 globally |
| Description | Appointed expert member of clinical and ethics/legal sub-group, and author of report. Presentation of findings at the Royal College of Paedicatric Child Health and Department of Health |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | CORAL and subsequent Cochrane review on robotic cystectomy |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | - |
| Description | Citation in subsequent frameowrk document |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | Changed the arrangements for distribution for research purposes of organs retrieved but not transplanted |
| Description | Co-opted onto BTS council to represent Basic Science |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Elected member of BTS Clinical Trials Committee |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://bts.org.uk/chapters-committees/clinical-trials-committee/clinical-trials-committee-members/ |
| Description | Expert reviewer and collaborator |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Description | House of Lords Regenerative Medicine Report (3 Centre PIs gave independent evidence) |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Influence on TTS policy on China |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Invited to small working group at the Human Tissue Authority- in view of publications writtenon the subject and published in high impact factor ethics/law journals |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Guideline Title | . |
| Description | NICE guidance published in the BJUI |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | . |
| Description | Policy Document to guide clinical practice |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Renal Replacement Therapy for Critically Unwell Adult Patients: Guidelines for best practice and service resilience during COVID-19. |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | This is a guideline to prepare for the NHS for copying with the increasing needs for renal replacement therapy during the COVID-19 pandemic. https://https//renal.org/wp-content/uploads/2020/10/DRAFT-guidelines-RRT-for-Critically-Unwell-Adult-Patients.pdf |
| Description | Scientific Advisory Board, DIREKT EC Framework Programme |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | The first international robotics training curriculum |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | - |
| Description | 6 x 4-year PhD studentships through Complement UK |
| Amount | £733,528 (GBP) |
| Organisation | Alexion Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Allergy, Immunology and Transplantation Research |
| Amount | $941,479 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 02/2016 |
| Description | Allergy, Immunology, and Transplantation Research |
| Amount | $25,920 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 07/2016 |
| Description | Capital Bid |
| Amount | £1,690,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2012 |
| End | 09/2015 |
| Description | Characterisation of glycan ligands recognised by collectin-11 in ischaemic kidney and development of a specific antagonistic probe |
| Amount | £907,007 (GBP) |
| Funding ID | MR/R010757/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Collectin-11 as a trigger of the innate immune response in renal transplantation |
| Amount | £560,440 (GBP) |
| Funding ID | MR/M012263/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 02/2018 |
| Description | Collectin-11 as a trigger of the innate immune response in renal transplantation |
| Amount | £560,440 (GBP) |
| Funding ID | MR/M012263/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Complement UK PhD studentships 2016 |
| Amount | £210,000 (GBP) |
| Organisation | Alexion Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 10/2016 |
| End | 09/2020 |
| Description | Design of Novel Immunotherapies for Prostate Cancer - from Bench to Bedside |
| Amount | £1,500,000 (GBP) |
| Organisation | Prostate Cancer Research Centre (PCRC) |
| Sector | Private |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 10/2019 |
| Description | Determining the role of coagulation proteases in the development of renal fibrosis |
| Amount | £316,572 (GBP) |
| Funding ID | MR/T000058/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2022 |
| Description | Developing the evidence base for an innovative anti-inflammatory/anti-fibrotic therapy |
| Amount | £79,468 (GBP) |
| Funding ID | MC_PC_18052 |
| Organisation | Kings Health Partners |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2020 |
| Description | Development of cytotopically modified antithrombotic agent for prevention of acute intra-graft thrombosis in transplantation |
| Amount | £1,829,783 (GBP) |
| Funding ID | 098300 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | EME programme award (Co-applicant with M Robson) |
| Amount | £1,168,806 (GBP) |
| Funding ID | 13/94/10 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 12/2018 |
| Description | Efficacy and Mechanism Evaluation (EME) |
| Amount | £300,000 (GBP) |
| Funding ID | 13/94/55 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 02/2019 |
| Description | Efficacy and Mechanism Evaluation (EME) Programme |
| Amount | £1,241,563 (GBP) |
| Funding ID | 13/94/10 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 04/2019 |
| Description | Establishing the optimising Transplant Survival Clinic |
| Amount | £37,317 (GBP) |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Department | Guy’s and St Thomas’ Kidney Patients' Association (GSTT KPA) |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 09/2011 |
| End | 03/2014 |
| Description | Exploring the Links Between Regulatory T cell Populations and Development of HLA Antibodies in Renal Patients Awaiting Transplantation. |
| Amount | £274,253 (GBP) |
| Funding ID | MR/T006560/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 05/2023 |
| Description | Fan Qu visit - CSC fellowship |
| Amount | £20,000 (GBP) |
| Organisation | University of Leeds |
| Department | China Scholarship Council |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 10/2015 |
| Description | Funding for 4-year PhD studentships (x2) from KCL |
| Amount | £200,000 (GBP) |
| Funding ID | MJKRAAR |
| Organisation | King's College London |
| Department | School of Medicine KCL |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 09/2017 |
| Description | Immune Tolerance Network |
| Amount | $27,000,000 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 02/2016 |
| Description | Immune Tolerance Network |
| Amount | $30,000 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 02/2017 |
| End | 01/2018 |
| Description | Impact Grant King's Policy Institute |
| Amount | £20,000 (GBP) |
| Funding ID | MJK9408 |
| Organisation | King's College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2013 |
| End | 12/2014 |
| Description | Intermediate Clinical Fellowship - Dr Nicholas Powell |
| Amount | £876,303 (GBP) |
| Funding ID | 101159/Z/13/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2018 |
| Description | Investigation into the efficacy of Mirococept in renal transplantation |
| Amount | £213,310 (GBP) |
| Funding ID | G1001197 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Investigator Driven Clinical Study Astellas |
| Amount | £76,000 (GBP) |
| Organisation | Astellas Pharma |
| Sector | Private |
| Country | Japan |
| Start | 10/2014 |
| End | 10/2015 |
| Description | KHP Challenge Fund |
| Amount | £73,882 (GBP) |
| Funding ID | R140807 |
| Organisation | King’s Health Partners |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2015 |
| Description | KHP R&D Challenge Fund |
| Amount | £96,708 (GBP) |
| Funding ID | R1405170 |
| Organisation | Guy’s & St Thomas’ Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 09/2015 |
| Description | KHP Research Grant |
| Amount | £91,000 (GBP) |
| Organisation | King’s Health Partners |
| Department | King's Health Partners Research and Development Challenge Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2013 |
| End | 10/2014 |
| Description | KRUK Clinical Training Fellowship to Dr Philippa Dodd |
| Amount | £258,741 (GBP) |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2017 |
| Description | Kidney Research UK - M Robson |
| Amount | £199,867 (GBP) |
| Funding ID | RP1/2015 |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 11/2018 |
| Description | Kidney Research UK Research Training Fellowship - Dr Philippa Dodd |
| Amount | £258,741 (GBP) |
| Funding ID | TF1/2014 |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2017 |
| Description | King's Health Accelerator Award |
| Amount | £130,213 (GBP) |
| Organisation | King's College London |
| Department | King's Commercialisation Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2017 |
| Description | King's Together |
| Amount | £18,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2018 |
| Description | King's Worldwide Partnership Fund |
| Amount | £1,984 (GBP) |
| Organisation | King's College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 04/2016 |
| Description | MRC Centenary Award 2013 |
| Amount | £30,000 (GBP) |
| Funding ID | PO Number 4050246766 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2012 |
| End | 06/2013 |
| Description | MRC Centenary Award for early career researchers |
| Amount | £45,000 (GBP) |
| Funding ID | MR/J006742/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2012 |
| End | 12/2012 |
| Description | MRC Centre Directors Capital Bid 2013: CEL (Cell Engineering Laboratory) |
| Amount | £203,000 (GBP) |
| Funding ID | MR/J006742/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 03/2015 |
| Description | MRC Centre Grant. MRC Centre for Transplantation |
| Amount | £1,694,050 (GBP) |
| Funding ID | MR/J006742/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC Centre for Transplantation Minor Equipment |
| Amount | £100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| End | 03/2018 |
| Description | MRC Clinical Training Fellowship for Dr Hannah Burton |
| Amount | £244,237 (GBP) |
| Funding ID | MR/M01813X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 08/2018 |
| Description | MRC Clinical Training Fellowship for Dr Hannah Wilkinson |
| Amount | £278,889 (GBP) |
| Funding ID | MR/P018513/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | MRC Clinical Training Fellowship for Dr Harriot Doiuthwaite |
| Amount | £223,234 (GBP) |
| Funding ID | MR/N020340/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 10/2019 |
| Description | MRC Clinical Training Research Fellowship for Dr Caroline Dudreuilh |
| Amount | £253,932 (GBP) |
| Funding ID | MR/S000852/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | MRC DPFS |
| Amount | £1,007,574 (GBP) |
| Funding ID | MR/N019334/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 05/2021 |
| Description | MRC DPFS: Regulatory T cells in Highly Sensitised Renal Patients to Improve Outcomes after HLA-Ab Incompatible Transplantation |
| Amount | £3,107,704 (GBP) |
| Funding ID | MR/T025573/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2020 |
| End | 12/2023 |
| Description | MRC Fellowship |
| Amount | £947,966 (GBP) |
| Funding ID | G0902288 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2010 |
| End | 09/2014 |
| Description | MRC Project Grant |
| Amount | £500,000 (GBP) |
| Funding ID | MR/M012263/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 12/2018 |
| Description | MRC Research Grant |
| Amount | £2,482,245 (GBP) |
| Funding ID | G1001197 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC project Grant (Co-applicant with G. Lombardi) |
| Amount | £483,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2013 |
| End | 01/2016 |
| Description | Marato TV3 Foundation |
| Amount | € 324,500 (EUR) |
| Organisation | La Marató de TV3 Foundation |
| Sector | Charity/Non Profit |
| Country | Spain |
| Start | 10/2013 |
| End | 10/2016 |
| Description | MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis |
| Amount | £200,000 (GBP) |
| Funding ID | RP38/2014 |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2014 |
| End | 11/2017 |
| Description | NIH research award |
| Amount | $308,873 (USD) |
| Funding ID | 5U01AI100807-03 |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 01/2015 |
| End | 06/2017 |
| Description | NIHR BRC Bridging Fellowship - Dr Niloufar Safinia |
| Amount | £66,989 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 09/2015 |
| Description | NIHR EME |
| Amount | £1,241,563 (GBP) |
| Funding ID | 13/94/10 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 05/2019 |
| Description | NIHR HS&DR (Health Services and Delivery Research) |
| Amount | £876,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 01/2020 |
| Description | National Institute of Health Research Efficacy and Mechanism Evaluation (EME) Programme |
| Amount | £1,677,143 (GBP) |
| Funding ID | 13/94/55 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 11/2020 |
| Description | Optimization of the potency, specificity and survival properties of engineered regulatory T cells to treat inflammatory liver diseases |
| Amount | £198,505 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2021 |
| End | 11/2024 |
| Description | Overcoming immunological barriers to regenerative medicine |
| Amount | £2,322,220 (GBP) |
| Funding ID | MR/L022699/1 |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | PROSPECTIVE LONGITUDINAL STUDY OF IWITH SCREEN FAILURES SECONDARY TO HISTOPATHOLOGY |
| Amount | $480,515 (USD) |
| Funding ID | 1R01DK114180-01 |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 08/2017 |
| End | 07/2020 |
| Description | Pilot funding for retinoid dietary intervention in ADPKD mice |
| Amount | £2,000 (GBP) |
| Funding ID | N/A |
| Organisation | PKD Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2013 |
| End | 06/2014 |
| Description | Project Grant Application - Targeting C5aR in chronic inflammation, renal fibrosis and late graft dysfunction |
| Amount | £464,744 (GBP) |
| Funding ID | MR/L020254/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2014 |
| End | 04/2017 |
| Description | Prolonging cardiac allograft survival by targeting the indirect antigen presentation pathway with an immunotoxin |
| Amount | £248,748 (GBP) |
| Funding ID | PG/17/52/33059 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2020 |
| Description | Prostate Cancer Research Centre King's College London |
| Amount | £1,500,000 (GBP) |
| Organisation | Prostate Cancer Research Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| Description | Quality in Organ Donation (QUOD) |
| Amount | £60,608 (GBP) |
| Funding ID | QUOD Centre |
| Organisation | NHS Blood and Transplant (NHSBT) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2016 |
| Description | ROTRF |
| Amount | £202,047 (GBP) |
| Organisation | Roche Organ Transplantation Research Foundation (ROTRF) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 10/2014 |
| End | 09/2016 |
| Description | Regulatory T cell treatment for the prevention of CAV in children receiving heart transplant |
| Amount | £401,383 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 12/2024 |
| Description | Roche Organ Transplantation Research Foundation |
| Amount | £200,000 (GBP) |
| Funding ID | 560883191 ROTRF |
| Organisation | Roche Organ Transplantation Research Foundation (ROTRF) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 10/2014 |
| End | 09/2016 |
| Description | Single Cell-Level Functional Proteomics and Genomics exemplified in Cancer and Immunology |
| Amount | £2,386,712 (GBP) |
| Funding ID | MR/M022927/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 06/2018 |
| Description | Single Cell-Level Functional Proteomics and Genomics exemplified in Cancer and Immunology |
| Amount | £237,939 (GBP) |
| Funding ID | MR/M022927/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Targeting C5aR in chronic inflammation, renal fibrosis and late graft dysfunction |
| Amount | £571,620 (GBP) |
| Funding ID | MR/L020254/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | The Urology Foundation |
| Amount | £75,000 (GBP) |
| Organisation | Urology Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 01/2019 |
| Description | The role of Wnt signalling in prostate cancer |
| Amount | £306,654 (GBP) |
| Organisation | Prostate Cancer Research Centre (PCRC) |
| Sector | Private |
| Country | United Kingdom |
| Start | 12/2014 |
| End | 04/2018 |
| Description | UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Lombardi) |
| Amount | £310,822 (GBP) |
| Funding ID | MR/L022699/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2017 |
| Description | UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Steve Sacks) |
| Amount | £295,551 (GBP) |
| Funding ID | MR/L022699/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2017 |
| Description | UK-AIH |
| Amount | £10,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 12/2018 |
| Description | Wellcome Trust New Investigator Award (Dr Claudia Kemper) |
| Amount | £1,519,891 (GBP) |
| Funding ID | 102932/Z/13/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 03/2019 |
| Description | Wellcome Trust Principal Research Fellowship |
| Amount | £4,692,044 (GBP) |
| Funding ID | 091823/Z/10/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Wellcome Trust Translation Award (Co-applicant with Richard Smith) |
| Amount | £1,300,000 (GBP) |
| Funding ID | 098300/Z/12/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2015 |
| Description | Wnt signalling in prostate cancer |
| Amount | £0 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 10/2020 |
| Title | An in vitro model for studying genes and functions regulated by endogenous RA/RAR |
| Description | Combining two inhibitors AGN193109, DEAB and a cell line mIMCD-3 cells, as well as other collecting duct cell lines, we have established an in vitro approach to defining endogenous RA/RAR activities, target mRNAs, microRNAs and other non-coding RNAs. This approach can be used for other similar studies, using the same cell line or different ones. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | We have published our work on mRNAs using this approach in PLOS One. We have again shown it worked perfectly on microRNAs, leading to a manuscript that will be published after ongoing validation. This can also lead to further grants. Other scientists can also be inspired to develop similar systems for studying functions of endogenous RA/RAR in other systems. |
| Title | Elispot Standardisation |
| Description | Measures number of cytokine-producing cells after stimulation in vitro |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | Standarization of method that will be used to stratify kidney transplant recipients if the trial is positive |
| URL | http://www.biodrim.eu/description.html |
| Title | GAMBIT cell and mRNA collection |
| Description | cells mRNA from blood serum urine mRNA fresh urine |
| Type Of Material | Biological samples |
| Year Produced | 2009 |
| Provided To Others? | No |
| Impact | Future biomarkers of tolerance to be developed |
| Title | GFP-C3 mouse |
| Description | Mouse engineered to express fluorescein-labelled complement protein (C3) that can be tracked in vivo. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2013 |
| Provided To Others? | No |
| Impact | The mouse has only just been generated. |
| Title | Humanised mouse model |
| Description | Immunodeficient mice reconstituted with human blood to study human immune responses in vivo and develop strategies to interfere with them. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2011 |
| Provided To Others? | No |
| Impact | Publications and future collaborations. |
| Title | Immunotoxin to prolong graft survival |
| Description | An immunotoxin that kills donor passenger leukocytes can induce indefinite survial of donor allografts |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | This can be adopted in the clinic to prolong graft survival in humans. |
| Title | Indices of Tolerance Array |
| Description | Data on mRNA array |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Access by other researchers PMID: 21827613 |
| URL | http://GSO.htm |
| Title | KALIBRE mRNA and cell collection |
| Description | PBMC stored in liquid nitrogen mRNA from blood plasma fresh urine - frozen - mRNA extracted from urine |
| Type Of Material | Biological samples |
| Year Produced | 2012 |
| Provided To Others? | No |
| Impact | Not yet |
| Title | Kidney glycan array |
| Description | Release of glycans from ischaemic human kidney |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | Potentially enables glycan array to identify biding ligands for collectin-11 |
| Title | Novel RARalpha agonists |
| Description | This will likely be a novel drug lead. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | RARalpha is the dominant isotype of RAR in both collecting ducts and podocyte cell lineages, where RAR signalling is found. Selectively activate RARalpha can avoid side effects of RARgamma (dry and itching skin) and RXR (potentially pro-fibrotic) and thus could become more selective renal therapy in AKI and CKD. |
| Title | Phospholipid Capture Enzyme Immunoassay (PCEIA) |
| Description | The PCEIA is a generic system for the assay of cytotopic agents (CTAs). CTAs are modified protein or peptides which possess the ability to bind to phosphatidyl serine (PS) and related acidic phospholipids in cell membranes. The assay uses PS deposited on the wells of microtitre plates as the capture step. The protein or peptide component of the CTA is then detected with a specific antibody followed by a secondary antibody linked to an enzyme component such as horseradish peroxidase. The signal is detected colorimetrically with an appropriate enzyme substrate. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | A PCEIA for the complement inhibitor Mirococept was initially developed in response to a regulatory requirement (from the UK MHRA) for an additional potency assay for this agent. It was reasoned that an assay which was dependent not only on the ability to bind PS but also on the antigenic identity of the CTA would be complementary to the existing biological assay for complement inhibitors which is cell-based. This proved to be the case and the new assay was incorporated into a revised MIrococept Investigational Medicinal Product Dossier (IMPD) filed in late 2013. We realized that the same capture step could be applied to all CTAs regardless of the modified "cargo". During 2014 we have validated this approach for the anticoagulant Thrombolexin and the complement terminal pathway inhibitor Cytectin. This work has been written up for publication and we expect it to contribute not only to the development of a range of CTAs but also to ultimate commercialization |
| Title | Ppbp null mice |
| Description | Ppbp null mice we re-derived at King's are proven fertile and develop normally, thus an excellent model for testing the roles for ppbp in a variety of disease models. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | This model is now being used to examine the roles for ppbp in late development of the urinary tract, platelet biology, endothelial-monocyte interaction, immunity, infection and kidney diseases. Once pilot data are appealing there will be new grant applications, etc. |
| Title | Rare-Luc mice |
| Description | This will allow quantitatively visualising RXR/RAR signalling at the whole animal, in tissues and at cellular levels. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Provided To Others? | No |
| Impact | This will allow quantitatively visualising RXR/RAR signalling at the whole animal, in tissues and at cellular levels. |
| Title | Refinement of heart transplant technique |
| Description | A new less traumatic method to perform heart transplant in mice |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | It is now published, others using the technique can easily learn it with the help of an on line video |
| Title | TRE-dnRAR transgenic mice |
| Description | This line of mice will enable conditional expression of a dominant negative mutant of RAR to achieve conditional repression of RXR/RAR signalling in the mice. Once interred with Hoxb7-Tet On mice, we can then achieve conditional repression of RXR/RAR signalling selectively in the collecting ducts in adult mice. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Provided To Others? | No |
| Impact | As RXR/RAR signalling is indispensable to kidney development, this line of transgenic mice will avoid renal abnormality induced by repression of RXR/RAR in embryonic mice and enable study of the roles for RXR/RAR signalling in both physiology and pathophysiology of adulthood. |
| Title | anti-human and mouse VISTA monoclonal antibidies |
| Description | antibodies specific to human and mouse VISTA |
| Type Of Material | Antibody |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | new target for immnotherapy |
| Title | laparoscopic renal transplantation |
| Description | an animal model for laparoscopic renal transplantation, a novel clinical technique, which has involved collaboration with Prof Campistol in Barcelona, and with the surgical department at St Georges hospital. The model is being refined with a view to translation to human subjects later this year. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Provided To Others? | No |
| Impact | The model is being refined with a view to translation to human subjects later this year. |
| Title | 100,000 genome project for NHS England |
| Description | Contribution of kidney samples/data on 2,252 patients |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | none so far |
| Title | BAUS National database |
| Description | National outcomes of radical prostatectomy |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Publicly available data |
| URL | http://WWW.BAUS.ORG.UK |
| Title | British Association of Urological Surgeons, |
| Description | National Publicly available database |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | First such national data on cancer patients |
| URL | http://www.baus.org.uk/ |
| Title | Genome-wide database |
| Description | Genome-wide kidney transplant database from 28 UK and Ireland centres on 8,900 donor and recipient pairs (who also donated DNA). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | Resource for further disease complications after transplantation. |
| Title | International Robotic Cystectomy Consortium |
| Description | Robotic cystectomy |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | . |
| Title | Liver Tolerance Database |
| Description | Database containing sequential liver histology from liver transplant recipients enrolled in immunosuppression withdrawal trials. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | - Identification of transient inflammatory changes in the liver allografts of patients undergoing successful immunosuppression withdrawal. - Has allowed us define the acceptable inclusion/exclusion criteria for future immunosuppression withdrawal trials. |
| Title | NHR-HIC |
| Description | Integration of anonymised clinical data and "omics" for research and clinical purposes |
| Type Of Material | Data handling & control |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | No impact yet. 4 collaborating groups: Cambridge, Oxford, Imperial and KCL. It will be expanded UK-wide within 3 - 5 years It will facilitate research and clinical practice in a large scale |
| URL | http://www.nihr.ac.uk/about/hic.htm |
| Title | NIHR-health informatics consortium in transplantation |
| Description | Part of the NIHR-HIC project for NHS England consisting of 6,300 samples |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | n/a |
| Title | Vattikui Collaborative Quality Initiative |
| Description | International outcomes of prostatectomy and partial nephrectomy |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | . |
| Description | Alexion Pharmaceuticals |
| Organisation | Alexion Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | We collaborated on an investigator led pre clinical study to determine the impact of complement inhibitor (anti-C5) on reperfusion injury in native and transplant kidneys. |
| Collaborator Contribution | Alexion Pharmaveuticals provided Chemicals, Consumables and animals to this study |
| Impact | The therapeutic antibody failed to penetrate into transplanted kidney and therefore helped to define types of injury that would not amenable to this particular therapeutic strategy. |
| Description | Anti inflammatory and anti thrombin - Duke University |
| Organisation | Duke University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | What the link embraces 1. Distinctive areas of strength that complement the academic plans at both Centres 2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills 3. Enhanced metrics for training in health services research 4. Benefits of cross-centre evaluation of clinical-academic programmes 5. Leveraging funding to support the proposed activities and goals |
| Collaborator Contribution | Research training and consumables including non human primates. |
| Impact | Abstract at the American Society for Transplantation |
| Start Year | 2015 |
| Description | Assessing the role of complement-mediated regulation of Th1 responses in health and disease |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We have discovered one of the molecular pathways controlling IFN-gamma ; 'shut down' in Th1 cells and the corresponding defect in RA patients T cells. We are now assessing this pathway in detail - as the 'basic science team' - and keep collaborating with the clinical team to asses if identified deregulation points can be predicted or corrected therapeutically in RA patients. |
| Collaborator Contribution | We have partnered with several clinicians working on rheumatoid arthritis (RA) at Guy's hospital. In addition, we are now included in an ongoing clinical trial at Guy's Hospital assessing factors that help predicting if and when RA patients can be 'weaned off' anti-TNF therapy. |
| Impact | "Grant money: 2011-2018. IMI (Innovative Medicine Initiative - FP7/2009) by the European Union. Understanding aberrant adaptive immunity mechanisms in human chronic immune-mediated diseases: rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. Application package jointly submitted by 14 European Research Institutions and 11 Biotechnology companies. Coordinating Director: Prof. Dr. T.W.J. Huizinga, Leiden University, Netherlands. €6.5 Mio. KingÂ' College portion: £680.000 Role: Leading Scientist (KingÂ's College Stream; Lead-PI: Andy Cope) 2011-2014 MRC Project Grant. The molecular and cellular basis of complement-mediated T helper 1 (Th1) differentiation and regulation. Kemper C, Cope A, Rebello-Mesa I and Lavender P. £860.000 Role: PI Peer reviewed publications: 1.Cardone, J, Le Friec, G, Vantourout, P, Roberts, A, Fuchs, A, Jackson, I, Suddason, T, Lord, G, Atkinson, JP, Cope, A, Hayday, A and Kemper, C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol 2010. 11(9):862-871. 2. Cope, A, Le Friec, G, Cardone, C and Kemper, C. The lifecycle of Th1 cells: molecular control of IFN-γ to IL-10 switching. TRENDS Immunol 2011. 32:278-286. 3. Cardone, C, Le Friec, G, and Kemper, C. CD46 in innate and adaptive immunity: An update. Clin Exp Immunol 2011. 164:301-311. 4. Heeger, P, and Kemper, C. Novel roles of complement in T effector cell regulation. Immunobiology. 2011. doi:10.1016/j.imbio.2011.06.004 Conference presentations/invited lectures: Immunology Seminar Series, Oxford University, Dunn School of Pathology; Complement and T cell homeostasis. 2010 Â'John Humphrey Seminar SeriesÂ' at Imperial College, London, UK; Complement: Tipping the balance between successful host defense and autoimmunity. 2010 Regional BSI group seminar series Cardiff University, UK; Complement during T cell activation: Timing (and the microenvironment) is key. 2010 BSI Annual Conference, Liverpool, UK; Complement, T cells and autoimmunity. 2011 Immunology Seminar Series, Cambridge University; Innate signals regulating Th1 immunity. 2011 Wright-Fleming Institute Seminar Series, Imperial College London; Towards a molecular Th1 life cycle signature. 2011 UCB, Slough, UK. Therapeutic interventions in Th1-mediated autoimmune disease states. 2011 8th International Conference on Innate Immunity, Chania, Greece: Innate immune signals in the regulation of Th1 responses. 2011 Annual BSI Â'Showcase of ImmunologyÂ', London, UK; CD46: Just a Notch up your common complement regulator." |
| Start Year | 2010 |
| Description | BIO-DRIM FP7 EU Consortium |
| Organisation | Charité - University of Medicine Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | We are the lead investigators in a multi-national clinical trial of immunosuppression discontinuation in liver transplantation. The trial involves clinical sites in UK, Germany, Belgium and Spain, and is funded in part by the EU FP7 BIO-DRIM Consortium. |
| Collaborator Contribution | Support on quality of life and health-economic analyses. Support on biomarker commercialisation strategy. |
| Impact | 2 publications: Feng S. et al. Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants. Gastroenterology 2018. DOI: 10.1053/j.gastro.2018.08.023. Londoño et al. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. Journal of Hepatology 2018 DOI: 10.1016/j.jhep.2018.04.012 |
| Start Year | 2013 |
| Description | CL-11 Ligand characterization |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We established the relationship on the basis of preliminary data on Collectin-11. We provided the research question in support of the successful grant application awarded by the MRC. |
| Collaborator Contribution | Specialist knowledge concerning carbohydrate arrays enabling exploration of the Collectin-11 ligand on renal tissue. |
| Impact | preliminary carbohydrate array work carried out and being further developed. |
| Start Year | 2014 |
| Description | Chelsea Therapeutics |
| Organisation | Chelsea Therapeutics |
| Country | United States |
| Sector | Private |
| PI Contribution | We have developed a biomarker for clinical trials. |
| Collaborator Contribution | The company provided a drug compound (an anti-folate) |
| Impact | We have published a paper, Pubmed ID: 18343249 |
| Start Year | 2007 |
| Description | Collaboration with UCB |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Formal consultancy arrangement with UCB concerning planning and delivery of a phase 2 clinical trial in renal transplant patients |
| Collaborator Contribution | UCB will provide a novel drug for this investigator-led study |
| Impact | none yet |
| Start Year | 2016 |
| Description | Collectin 11 and lung inflammation with the University of Denver |
| Organisation | University of Colorado Denver |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Sent the breeding pairs of mice with deficiency of collectin 11 and telephone conference call set up. |
| Collaborator Contribution | Expertise on the animal model of lung disease |
| Impact | None so far |
| Start Year | 2016 |
| Description | Collectin 11 at the front line of tissue response stress - Complement UK research studentship |
| Organisation | Alexion Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | Prepared PhD project proposal and being the primary supervisor of the PhD student |
| Collaborator Contribution | Full PhD scholarship (4 years) |
| Impact | Obtained a full PhD studentship (4 years) |
| Start Year | 2013 |
| Description | Cost action BM1305. "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT)" |
| Organisation | European Cooperation in Science and Technology (COST) |
| Country | Belgium |
| Sector | Public |
| PI Contribution | ME and my team participate in 2 working subgroups "Flow Cytometry", "mRNA-QPCR analysis" and "Functional Analysis". Mainly in method harmonisation process |
| Collaborator Contribution | Provide talks, information, SOPs and collaborating in writing a manuscript |
| Impact | 1. Science Translational Medicine 09 Sep 2015: Vol. 7, Issue 304, pp. 304ps18 DOI: 10.1126/scitranslmed.aaa7721 2. 3 x Joint Management Committee (MC) and Working Groups (WG) Meetings have taken place in Newcastle (2014), Lisbon (2015) and Gdansk (2015) |
| Start Year | 2013 |
| Description | Cost action in preparation. "Immuno modulation strategies to improve outcomes in transplanted children" |
| Organisation | University Hospital La Paz |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Establishing objectives and partnership |
| Collaborator Contribution | n/a |
| Impact | n/a |
| Start Year | 2016 |
| Description | Development of Cyclic Peptide libraries for discovery of novel prostate cancer therapeutics |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Developing single cell epigenetic analysis techniques of cyclic peptide epigenetic modification |
| Collaborator Contribution | Liam Fotheringham is developing the cyclic peptide libraries and Oscar Cez is developing fluidigm techniques for single cell epigentic information capture. |
| Impact | Innovate/BBSRC grant IBC4 application pending |
| Start Year | 2015 |
| Description | Development of Cyclic Peptide libraries for discovery of novel prostate cancer therapeutics |
| Organisation | Ingenza Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developing single cell epigenetic analysis techniques of cyclic peptide epigenetic modification |
| Collaborator Contribution | Liam Fotheringham is developing the cyclic peptide libraries and Oscar Cez is developing fluidigm techniques for single cell epigentic information capture. |
| Impact | Innovate/BBSRC grant IBC4 application pending |
| Start Year | 2015 |
| Description | Development of Cyclic Peptide libraries for discovery of novel prostate cancer therapeutics |
| Organisation | Roslin Biocentre Ltd |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Developing single cell epigenetic analysis techniques of cyclic peptide epigenetic modification |
| Collaborator Contribution | Liam Fotheringham is developing the cyclic peptide libraries and Oscar Cez is developing fluidigm techniques for single cell epigentic information capture. |
| Impact | Innovate/BBSRC grant IBC4 application pending |
| Start Year | 2015 |
| Description | Emory |
| Organisation | Emory University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Clinical fellows exchange programme adding value to joint research projects between Emory and KCL. |
| Collaborator Contribution | What the link embraces 1. Distinctive areas of strength that complement the academic plans at both Centres 2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills 3. Enhanced metrics for training in health services research 4. Benefits of cross-centre evaluation of clinical-academic programmes 5. Leveraging funding to support the proposed activities and goals |
| Impact | Dr Stuart Hurst, a medical trainee from Emory, started the collaborative programme by joining the MRC Centre for Transplantation for 2 years in July 2013, under Professors Anthony Dorling and Steven Sacks' supervision. Dr Blayne Sayed from Emory has joined the MRC Centre in July 2014 under the supervision of Professor Alberto Sanchez Fueyo. The MRC Centre for Transplantation awarded MRC Centre two Emory Bridging Fellowships and appointed two female surgical trainees to carry out research projects at Emory in the USA. Their sabbaticals are due to start in 2015. |
| Start Year | 2013 |
| Description | FP7 Consortium |
| Organisation | ALTA |
| Country | Italy |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Academic Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Astellas Pharma |
| Country | Japan |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Bristol-Myers Squibb |
| Country | United States |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Catalan Health Institute (ICS) |
| Department | University Hospital of Bellvitge (HUB) |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Cellogic GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Charité - University of Medicine Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Genome Identification Diagnostics GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Immunotech S.A.S. |
| Country | France |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Institute for Clinical and Experimental Medicine (IKEM) |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Milenia Biotec GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | TcLand Expression |
| Country | France |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University Hospital of Nantes |
| Country | France |
| Sector | Hospitals |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University of Hamburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University of Regensburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | GAMBIT consortium |
| Organisation | Cardiff and Vale University Health Board |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | East Kent Hospitals University NHS Foundation Trust |
| Department | Renal Services East Kent Hospitals University |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Great Ormond Street Hospital (GOSH) |
| Department | Renal Department GOSH |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Hull and East Yorkshire Hospitals NHS Trust |
| Department | Renal Hull and East Yorkshire |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | King's College Hospital NHS Foundation Trust (NCH) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Leicester General Hospital |
| Department | Renal Unit |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Manchester University NHS Foundation Trust |
| Department | Renal Care |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Department | Renal NHSGGC |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Queen Alexandra Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Royal Free London NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Salford Royal NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Department | Renal Unit Sheffield Teaching Hospitals |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | St George's Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GP-TCM |
| Organisation | University of Mons |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | I advised the research design and drafted part of the project and provided critical review and revision. |
| Collaborator Contribution | Everyone brings in their perspectives and literature study outcomes in terms of integrated toxicological approaches to herbal medicines. I provided my perspectives as the PI of the GP-TCM project and as a nephrologist. |
| Impact | his a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary |
| Start Year | 2007 |
| Description | Immune Tolerance Network |
| Organisation | Immune Tolerance Network |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Myself and my research team are participating as mechanistic investigators in 3 US multi-centre clinical trials of immunosuppression withdrawal in liver transplantation: iWITH (paediatric liver transplantation), OPTIMAL (adult liver transplantation) and ARTEMIS (cell therapy trial in adult liver transplantation). Our contributions are: 1) scientific input into the design of the experimental plan of the studies; 2) performance of high-throughput gene expression analyses on biological specimens collected as part of the trials; 3) multi-parameter bioinformatic analysis of clinical and molecular data; 4) contribution to dissemination of the results. |
| Collaborator Contribution | The Immune Tolerance Network is providing biological specimens and funds to conduct the transcriptional studies, as well as the associated meta-data to perform the multi-parameter analysis. |
| Impact | 1 publication: Feng S. et al. Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants. Gastroenterology 2018. DOI: 10.1053/j.gastro.2018.08.023 |
| Start Year | 2012 |
| Description | Islet research group Dresden |
| Organisation | University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Sharing of human islet resources; collaborative grant application for trial of implantable device |
| Collaborator Contribution | Our team provide human islets for research and we are about to start a King's based Diabetes UK funded study of implanting minimal islet mass in an immune isolating device in adults with type 1 diabetes as a pilot trial. £ 79020 has been awarded from Diabetes UK. |
| Impact | 1st successful grant application |
| Start Year | 2014 |
| Description | Jean-Paul Decuypere ERA-EDTA fellowship |
| Organisation | Catholic University of Louvain |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | ongoing scientific collaboration, support by offering space ad facilities available for the research to be carried out and shared authorship of any publications that may arise form this collaboration; enabled fellow to obtain an ERA-EDTA fellowship. |
| Collaborator Contribution | Bring expertise in autophagy tot he Centre and the ongoing research programme on Complement research. |
| Impact | ERA-EDTA fellowship |
| Start Year | 2014 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Addenbrooke's Hospital |
| Department | Liver Transplant Team |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | August Pi i Sunyer Biomedical Research Institute |
| Department | Hospital Clinic of Barcelona |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Brussels Saint-Luc University Hospital (UCL) |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Charité Campus Virchow - Hospital |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Hannover Medical School |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Queen Elizabeth Hospital Birmingham |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Royal Free Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | University Hospitals Leuven |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | MRC Centre for Transplantation |
| Organisation | King's College London |
| Department | MRC Centre for Transplantation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Team has become merged within the centre |
| Collaborator Contribution | Increased collaboration with Richard Smith, Steve Sacks, Gio Lombardi and Maria Hernandez-Fuentes. All have had significant intellectual input into the work |
| Impact | Being within the MRC Centre, within King's College London, within Guy's Hospital has significantly contributed to success in applications to British Heart Foundation, Kidney Research UK and commercial organisations for research funding. |
| Start Year | 2009 |
| Description | NIH Xenotransplantation at Pittsburgh |
| Organisation | University of Pittsburgh |
| Department | Thomas E Starzl Transplantation Institute |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaborator on NIH-funded Xenotransplantation programme. Latterly, advisor to renewed prgramme |
| Collaborator Contribution | PhD student to work/train in my lab. Collaboration to supply membrane tethered hirulog (thrombalexin) 2013 |
| Impact | Multiple papers, reported elsewhere - 1st author Lin CC |
| Start Year | 2006 |
| Description | Novartis |
| Organisation | Novartis |
| Department | Transplantation & Immunology |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | Two way sharing of data and techniques - including a trip to Basel in August 2011 to visit Novartis Global Research and to give a talk |
| Collaborator Contribution | Financial assistance, technical help |
| Impact | Paper in preparation. |
| Start Year | 2011 |
| Description | ORGANTRANS H2020 EU Consortium: 'Organ 3D printing for liver regenerative medicine' |
| Organisation | Leibniz Institute for Interactive Materials |
| Country | Germany |
| Sector | Private |
| PI Contribution | My research group's contribution is to define how the inflammatory microenvironment present in the setting of liver failure influences liver organoid viability. |
| Collaborator Contribution | The aims of the project are to replace liver transplantation for end-stage liver failure patients through the development of a liver tissue 3D printing platform. The project will cover the entire development cycle from cell source and tissue engineering through the trials allowing for early adoption of its results in clinical practice. Importantly, this research will create novel technologies that can be applied to other organ systems in regenerative medicine. |
| Impact | This is a multidisciplinary collaboration with an overall budget of € 6,301,156.25 involving partners in Germany, Netherlands, Czechia, Belgium, and UK with expertise in liver cell biology, organoid generation, liver inflammation, biogengineering and commercial. |
| Start Year | 2020 |
| Description | ORGANTRANS H2020 EU Consortium: 'Organ 3D printing for liver regenerative medicine' |
| Organisation | Swiss Center for Electronics and Microtechnology |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | My research group's contribution is to define how the inflammatory microenvironment present in the setting of liver failure influences liver organoid viability. |
| Collaborator Contribution | The aims of the project are to replace liver transplantation for end-stage liver failure patients through the development of a liver tissue 3D printing platform. The project will cover the entire development cycle from cell source and tissue engineering through the trials allowing for early adoption of its results in clinical practice. Importantly, this research will create novel technologies that can be applied to other organ systems in regenerative medicine. |
| Impact | This is a multidisciplinary collaboration with an overall budget of € 6,301,156.25 involving partners in Germany, Netherlands, Czechia, Belgium, and UK with expertise in liver cell biology, organoid generation, liver inflammation, biogengineering and commercial. |
| Start Year | 2020 |
| Description | ORGANTRANS H2020 EU Consortium: 'Organ 3D printing for liver regenerative medicine' |
| Organisation | Utrecht University |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | My research group's contribution is to define how the inflammatory microenvironment present in the setting of liver failure influences liver organoid viability. |
| Collaborator Contribution | The aims of the project are to replace liver transplantation for end-stage liver failure patients through the development of a liver tissue 3D printing platform. The project will cover the entire development cycle from cell source and tissue engineering through the trials allowing for early adoption of its results in clinical practice. Importantly, this research will create novel technologies that can be applied to other organ systems in regenerative medicine. |
| Impact | This is a multidisciplinary collaboration with an overall budget of € 6,301,156.25 involving partners in Germany, Netherlands, Czechia, Belgium, and UK with expertise in liver cell biology, organoid generation, liver inflammation, biogengineering and commercial. |
| Start Year | 2020 |
| Description | Requirement of complement C3 for transplant tolerance induction |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led to the initial observation that C3 deficient mice were resistant to tolerance induction. |
| Collaborator Contribution | Provided a Clinical Fellow with an interest in complement and transplantation. This has enabled a new scientific question to be addressed. |
| Impact | The initial results showing the requirement for C3 in tolerance to skin grafts was presented at an international meeting. |
| Start Year | 2008 |
| Description | Role of CD39 in T-reg and Th17 plasticity |
| Organisation | Beth Israel Deaconess Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Investigating the role of CD39 in shaping the balance between T-regs and Th17 cells in health, IBD and animal models of colitis |
| Collaborator Contribution | Provided equipment, consumables and animals |
| Impact | Nine peer-review papers (PMID: 22387392, 23787765, 23292173, 25042541, 25034284, 24681654, 22965858, 25172498 and 24505337) and six abstracts that have been accepted as oral presentations or posters at the Annual Meeting of the American Association of Immunologists (Boston, 4-8 May 2012), the European Congress of Immunology (Glasgow, 5-8 September 2012), the Digestive Disease Week (Orlando, 18-21 May 2013 and Chicago, 3-6 May 2014), the American Association for the Study of Liver Diseases (Boston, 9-13 November 2013). The poster presented at DDW in 2013 was awarded 'poster of distinction'. |
| Start Year | 2010 |
| Description | SIMULATE |
| Organisation | British Association of Urological Surgeons |
| Country | United Kingdom |
| Sector | Learned Society |
| PI Contribution | First and largest randomised trial of predictive validity of simulation |
| Collaborator Contribution | 100 trainees, 2500 patients |
| Impact | Program grant from The uROLOGY fOUNDATION |
| Start Year | 2016 |
| Description | SIMULATE |
| Organisation | City of Guangzhou |
| Country | China |
| Sector | Public |
| PI Contribution | First and largest randomised trial of predictive validity of simulation |
| Collaborator Contribution | 100 trainees, 2500 patients |
| Impact | Program grant from The uROLOGY fOUNDATION |
| Start Year | 2016 |
| Description | SIMULATE |
| Organisation | University of East Anglia |
| Department | Health and Social Sciences Research Institute EAU |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | First and largest randomised trial of predictive validity of simulation |
| Collaborator Contribution | 100 trainees, 2500 patients |
| Impact | Program grant from The uROLOGY fOUNDATION |
| Start Year | 2016 |
| Description | STIFF FLOP |
| Organisation | European Commission |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | Design, development and validation of an octopus inspired soft robot |
| Collaborator Contribution | ? |
| Impact | 200 publications, over 30 presnetations in international meetings, IEEE workshops, press coverageby the BBC, MULTIDICIPLINARY COLLABORATION between engineers,computer scientists,simulation experts and surgeons |
| Start Year | 2012 |
| Description | Studies on collectin 11 in renal ischaemia-reperfusion injury |
| Organisation | University of Leicester |
| Department | Department of Infection, Immunity and Inflammation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are the principle investigators on a grant that funds this research. This includes animal models for native and transplanted kidneys and cell culture studies |
| Collaborator Contribution | Expertise on the lectin pathway. |
| Impact | Journal of Clinical Investigation publication in press. |
| Start Year | 2015 |
| Description | Studies on the antagonism of CD59 as an anti-tumour strategy |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This project concerns the cytotopic modification of a peptide antagonist of CD59. My group has provided recombinant human CD59 in both cytotopic and unmodified forms. We have also provided a cytotopic reagent to permit the modification of the antagonist. |
| Collaborator Contribution | Our partners have undertaken structural studies on CD59 and modified CD59 binding to liposomes as a model for cellular interaction. |
| Impact | Part of the structural work has been published in 2013 |
| Start Year | 2012 |
| Description | The KCL-Belgium-China herbal toxicity axis |
| Organisation | University Libre Bruxelles (Université Libre de Bruxelles ULB) |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | I led the conception, research design and oversaw the whole project. |
| Collaborator Contribution | Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology & Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012. |
| Impact | This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary |
| Start Year | 2007 |
| Description | The KCL-Belgium-China herbal toxicity axis |
| Organisation | University of Mons |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | I led the conception, research design and oversaw the whole project. |
| Collaborator Contribution | Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology & Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012. |
| Impact | This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary |
| Start Year | 2007 |
| Description | The KCL-Belgium-China herbal toxicity axis |
| Organisation | Zhejiang University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | I led the conception, research design and oversaw the whole project. |
| Collaborator Contribution | Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology & Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012. |
| Impact | This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary |
| Start Year | 2007 |
| Description | The KCL-Belgium-HKU herbal fibrosis axis |
| Organisation | University of Hong Kong |
| Country | Hong Kong |
| Sector | Academic/University |
| PI Contribution | I led the conception, research design and oversaw the whole project. |
| Collaborator Contribution | Feng brought in knowledge and resources on Chinese herbal medicine; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez, as well as King's academic co-authors Hendry and Hylands are members of the GP-TCM Research Association that I led to establish in 2012. |
| Impact | This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary |
| Start Year | 2007 |
| Description | The KCL-Belgium-HKU herbal fibrosis axis |
| Organisation | University of Mons |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | I led the conception, research design and oversaw the whole project. |
| Collaborator Contribution | Feng brought in knowledge and resources on Chinese herbal medicine; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez, as well as King's academic co-authors Hendry and Hylands are members of the GP-TCM Research Association that I led to establish in 2012. |
| Impact | This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary |
| Start Year | 2007 |
| Description | Therapeutic inhibition of collectin-11 |
| Organisation | Apollo Therapeutics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Designed and pre-tested the inhibitor |
| Collaborator Contribution | Funding to further development of inhibitor |
| Impact | Efficacy testing in vitro |
| Start Year | 2022 |
| Description | UK Autoimmune Hepatitis Consortium |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Participation in prospective follow-up cohort studies, GWAS, eQTL and Epigenetics |
| Collaborator Contribution | Creating a blood and tissue bank where samples (and data generated from their analysis) can be accessed and used |
| Impact | Started determination of gene expression profile on liver biopsy samples |
| Start Year | 2014 |
| Description | Use of C5a-receptor humanised mice to evolve a treatment strategy in renal infections |
| Organisation | ChemoCentryx |
| Country | United States |
| Sector | Private |
| PI Contribution | The company is one of my collaborators on the recently awarded MRC project grant |
| Collaborator Contribution | By providing C5aR antagonist andhuman C5aR transgenic mice |
| Impact | Obtained a MRC grant |
| Start Year | 2013 |
| Description | W Zhou |
| Organisation | Xi'an Jiaotong University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | . |
| Collaborator Contribution | . |
| Impact | . |
| Start Year | 2012 |
| Description | Xi'an Jiaotong University, China |
| Organisation | Xi'an Jiaotong University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Cooperation on a research project which has involved a senior post-doctoral scientist visiting China for 8 weeks |
| Collaborator Contribution | They will provide the animals and team to assist in performance of experiments |
| Impact | Awarded a King's Worldwide Partnership Fund Award to assist with the collaboration |
| Start Year | 2013 |
| Title | METHOD OF DETERMINING KIDNEY TRANSPLANTATION TOLERANCE |
| Description | The present invention relates to a method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers. The present invention also relates to a kit comprising reagents for detecting the levels of the biomarkers. The present invention also relates to a sensor for detecting the expression levels of a plurality of genes that can be used to determine an individual's transplantation tolerance. |
| IP Reference | WO2011138609 |
| Protection | Patent application published |
| Year Protection Granted | 2011 |
| Licensed | Commercial In Confidence |
| Impact | A method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers |
| Title | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF |
| Description | The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates aCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon aCD3/aGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed |
| IP Reference | US2012195894 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | No |
| Impact | Currenlty evaluating multiple term sheets from Pharma and will likely close an agreement in the next 6 months. |
| Title | Regulatory T Cell Mediator Proteins and Uses Thereof |
| Description | The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates alphaCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon alphaCD3/alphaGITR stimulation. This protein has been designated T-sTNE Proteins, antibodies, activated T cells and methods for using the same are disclosed. |
| IP Reference | US2008287358 |
| Protection | Patent granted |
| Year Protection Granted | 2008 |
| Licensed | Yes |
| Impact | Yes. To JNJ. A licensing agreemnt >$150 million dollars. Therapeutic antibodies are being developed. |
| Title | 3D printing |
| Description | King's - Vattikuti Institute of Robotic Surgery Funding |
| Type | Therapeutic Intervention - Surgery |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2017 |
| Development Status | Actively seeking support |
| Clinical Trial? | Yes |
| Impact | Reducing positive margins in prostate cancer after radical prostatectomy |
| Title | A method for evaluating transplantation tolerance |
| Description | Diagnostic test to identify tolerance in kidney transplant recipients. We are developing the application strategy for patients. Needs a biomarker-led clinical trial that has not been funded yet. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | On hold |
| Impact | If the clinical trial shows clinical benefit for the patients who are in the biomarker-led group, we will have a tool to personalise the post-transplant management of a set of patients (5-15%) that will mean less immunosuppression, with the lower rate of secondary events this has and better quality of life. |
| Title | ABO Antibody Titres in Adult Patients Waiting for a Transplant |
| Description | Everybody has antibodies. In kidney transplantation, the important antibodies are blood group (ABO) and tissue type (HLA). We would like to measure the antibody strength (titre) of ABO-blood group antibodies for renal failure patients on the deceased donor waiting list. These ABO-blood group antibodies vary between people which is why we want to measure them in a large number of patients. We would also like to know if these antibody levels and other cells associated with the antibody response change with time which is why we plan to test them at 0, 6 & 12 months. At the moment, we measure antibody levels to different tissue types (HLA) for patients on the deceased donor list every 3 months, and we would time these tests to coincide as we would like to know if the strength of blood group (ABO) antibodies is in any way related to the strength of tissue type (HLA) antibodies. We don't routinely test ABO-blood group antibody strength unless a patient is having a live donor blood group incompatible transplant. This kind of transplant requires antibody removal before the transplant can go ahead safely. For some patients with weak (titre) blood group antibodies it is possible to have a transplant without antibody removal. ABO blood group incompatible transplantation from a deceased donor is not normally performed. We hope that by doing this study, we will identify how many patients have weak enough blood group antibodies to allow a blood group incompatible transplant without needing antibody removal. This might mean that they could be listed to accept more kidneys, which might make a deceased donor transplant more likely. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | n/a |
| URL | http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14694 |
| Title | Antithrombotic agent (PTL004) |
| Description | It has been found that linkage of anticoagulant peptides to membrane-localising ("cytotopic") reagents generates conjugates which are capable of inhibiting thrombin when attached to cell surfaces. This enables organs to be anticoagulated by perfusion ex-vivo prior to transplantation into the recipient. For the first time, it appears to be possible to separate local antithrombotic effects from systemic pharmacological ones using a readily translatable therapeutic agent. It may be possible to control thrombosis in transplantation (for example, in pancreatic and islet cell transplantation and in the prevention of antibody-mediated acute rejection) using this approach. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2009 |
| Development Status | Under active development/distribution |
| Impact | First product of its kind enabling prevention of Thrombosis in an organ transplant without having to anti-coagulate the recipient. Potential use in organs transplanted into pre-sensitised recipients. |
| Title | Beta Air |
| Description | Immuno isolating device for implantation of islet cells, with associated oxygen chamber. Due to start clinical trial. |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | Increased collaboration with islet team at Dresden through the process of developing this study |
| Title | Clinical study of MCMV5322A/MCMV3068A in kidney transplant recipients at high risk for CMV disease |
| Description | An international multicentre randomised controlled trial of an experimental drug in kidney transplant patients to prevent infection from a virus called cytomegalovirus (CMV). CMV can cause fever and fatigue, and can damage important organs, including the transplant. In this study, patients will get either placebo (a non-active substance) or the active study drug. The trial hopes to show that this new drug is safe and effective. The trial is funded and sponsored by Genentech pharmaceuticals. Recruitment has now closed but trial participants remain under active follow-up |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | x |
| URL | http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-002245-37-NO |
| Title | Cytotopic human interleukin 15 |
| Description | Modified human cytokine designed to generate regioselective immune stimulation within human tumours. Principle source of funding: Prostate Cancer UK/Heathside Fund |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2012 |
| Development Status | Under active development/distribution |
| Impact | N/A |
| Title | DECISIONS |
| Description | Aim to develop a novel method by which the risk associated with biomarker-led care can be adjusted to individual patient's circumstances. • Objectives: a) to identify the level of risk that patients may be willing to take, and investigate whether this is related to their symptom burden and quality-of-life, and b) to elicit attitudes to risk and uncertainty and the range of influences affecting patients' choice and decision making. • Mixed method study. a) Quantitative: Modified Standard Gamble to measure patient's willingness to take biomarker-led care depending on different levels of risk (sensitivity and specificity). Quality-of-life and symptom burden questionnaires will also be completed. b) Qualitative study comprises in-depth semi-structured interviews to investigate influences on choices and decision-making. • Hypothesis: high symptom burden and low quality of life is positively associated with a willingness to take risks associated with less accurate biomarker tests. Qualitative interviews will inform whether risk perception is related to particular factors other than symptom burden. We anticipate this study will develop the methodology to incorporate patient's preference into the translation of biomarker tests into clinical practice. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | NOT YET CURRENTLY DATA COLLECTING |
| Title | EMPIRIKAL Trial |
| Description | The medical product is a protein therapeutic which consists of a fragment of the complement regulator known as CR1 coupled to a membrane-binding tail. It is introduced into the donor kidney prior to transplantation. The study is to determine impact on delayed graft function (ischaemia-reperfusion injury). We completed recruitment of the 1st cohort of patients in 2016 and completed follow up in 2017. We will complete the data analysis by April 2018. There is an ongoing dosing/toxicity study in pig kidney, with a view to submitting a further clinical evaluation study proposal based on the pig study and cohort 1 data, expected submission 2019. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2018 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | A second therapeutic agent (anti thrombin) using the same targeting modality for use in kidneys transplanted into highly sensitized recipients is being prepared for clinical evaluation, based on the knowledge and skills derived from the above study. |
| URL | http://www.isrctn.com/ISRCTN49958194 |
| Title | Empirikal-Mirococept |
| Description | Membrane - interactive complement inhibitor used by ex vivo perfusion into isolated organ. About to enter definitive Phase II study. Drug manufacture completed to accepted standard. MHRA approved. Patient recruitment imminent. Souce of funding: MRC DCS grant. Recruitment began in July 2015 and 19 patients are now undergoing treatment. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2006 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Validation of the membrane-binding (cytotopic) approach used in Mirococept and the consequent development of this technology as a platform. Large scale manufacture and quality assessment for clinical trial completed. Completed investigators brochure. Ethics approved. MHRA approved. Patient recruitment open. |
| URL | http://www.mykidney.org/Research/ResearchAtGuys.aspx |
| Title | Evaluation of immune function in patients with acute kidney injury; Immune function in AKI |
| Description | active recruitment of patients since 2013. We are measuring immune function in 3 cohorts: patients with acute kidney injury (AKI), patients with systemic inflammatory response syndrome (SIRS) and patients without AKI and without SIRS. The aim is to deterimine whether AKI per se affects immune function. |
| Type | Support Tool - For Fundamental Research |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | results will serve to improve the knowledge of the impact of AKI and may help to explain the serious short- and long-term comorbidities of AKI. |
| Title | GAMBIT Genetic Analysis and Monitoring of Biomarkers of Immunological Tolerance |
| Description | Up to now it has been impossible to determine if a patient has developed tolerance to their graft as there have been no validated biomarkers that can be used to define immunological tolerance in kidney transplant recipients. Even if complete elimination of the immunosuppressants was not possible, lowering the doses of each drug might be expected to benefit patients by potentially reducing the above mentioned risks. However the benefits of minimizing immunosuppression must be weighed against the risks of precipitating acute rejection or propagating chronic transplant dysfunction. GAMBIT study In the present study we propose to capitalise on these established collaborations and validate a common biomarker set of tolerance, using newly recruited kidney transplant recipients, to get closer to fully translating these results to a clinically applicable diagnostic test of tolerance. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | currently recruiting |
| URL | http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=7521 |
| Title | Genomics of drug induced renal injury (DIRECT) |
| Description | active recruitment of patients commenced in March 2014. We are actively recruiting patients who have biochemical or histological evidence of acute kidney injury following administration of one of 40 drugs. The genetic profile wil be determined using blood and urine samples. The objective is to investigate if a genetic predisposition exists for the development of drug induced renal injury. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | provides the opportunity of personalised medicine |
| URL | http://www.saeconsortium.org/ |
| Title | Kalibre Kidney Allograft Immunological Biomarkers of Rejection Episodes |
| Description | The present "gold standard" test for diagnosis of Acute Rejection (AR) remains histological examination of a biopsy, and a key diagnostic feature is infiltration of the graft with cells of the immune system, especially lymphocytes. Gene products involved in lymphocyte migration, activation, effector pathways and regulation might provide early targets in the diagnosis of AR. In this study we aim to provide a reliable set of genes that could predict acute rejection obtaining serial measurements of gene expression in each patient. measurements: PBMC stored in liquid nitrogen mRNA from blood plasma fresh urine - frozen - mRNA extracted from urine |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | non yet sample collection |
| Title | LITE trial: Low-dose IL-2 to expand endogenous Tregs and achieve tolerance in liver transplantation |
| Description | The purpose of the trial is to assess the capacity of low doses of IL-2 to expand endogenous regulatory T cells and promote the development of operational tolerance following liver transplantation. Phase IV, open-label, activity, safety and efficacy, prospective, single-arm clinical trial in which liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication. Based on the IL-2 activity and safety after 1 month of treatment in the first 8 participants, the study will continue or it will terminate. In participants with a satisfactory increase in circulating Tregs after 1 month of IL-2 therapy, treatment will be maintained for 5 additional months while immunosuppressive drugs are gradually discontinued over a 3 month period. Efficacy will be determined by assessing the proportion of subjects who achieve successful immunosuppression withdrawal defined by the absence of rejection and a rejection free biopsy at 1 year following discontinuation of immunosuppression. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The development process of the trial has allowed the set up a medication circuit to manufacture and administer IL-2 to outpatient liver transplant recipients, and it has included a pilot study in which IL-2 was administered to patients with autoimmune liver disease. |
| URL | https://clinicaltrials.gov/show/NCT02949492 |
| Title | Liquid biopsy |
| Description | Using urinary microRNAs to inform progression of CKD. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2016 |
| Development Status | Actively seeking support |
| Impact | The results could also inspire personalised treatment using analogues of selected miRNAs. |
| Title | Membrane targeted anti-thrombin PTL006 |
| Description | A membrane targeted anti-coagulant for intented use in donor kidneys transplanted into high risk (highly sensitised) recipients. Currently at proof-of-principle stage in rat model. Current funding - MRC Centre Grant Directors Initiative. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2010 |
| Development Status | Under active development/distribution |
| Impact | Patent application registered. |
| Title | ORGANOX |
| Description | A multicentre randomised controlled trial to compare the efficacy of ex-vivo normothermic machine perfusion with static cold storage in human liver transplantation. The standard method of storing and transporting a liver for transplantation is to perfuse with a cold perfusion solution and store the liver in an ice box. To optimise the condition of such higher risk organs there is increased interest in continuous perfusion of the organ with blood at normal body temperature (normothermic perfusion). Livers will be randomly allocated to static cold storage (control group) or normothermic machine perfusion using the OrganOx metra device (study group). Recipients will then undergo transplantation and be managed according to standard local protocols. The two groups will be compared to investigate the potential benefit of normothermic machine perfusion. The trial is funded by the European Union Seventh Framework Programme (FP7): the COPE study (Work Package WP2). |
| Type | Products with applications outside of medicine |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2014 |
| Development Status | Actively seeking support |
| Clinical Trial? | Yes |
| Impact | Several studies demonstrate that the quality of preservation can be improved substantially by warm perfusion, by combining the avoidance of cooling with the maintenance of a supply of oxygen and nutrition |
| URL | http://www.organox.com/products/organ-asessment/ |
| Title | OuTSMART |
| Description | Treatment of kidney disease accounts for a significant proportion of NHS spending. Although transplantation is the best treatment for kidney failure, most transplants do not survive for the recipient's natural lifespan, but instead fail after 10-12 years. Damage by the immune system, called 'chronic rejection' accounts for 50% of failing transplants and it is now possible to identify patients at risk by screening for 'HLA antibodies' in the blood. This application is to test a screening and treatment protocol for antibodies in a randomised controlled trial. Those with antibodies will be randomised into biomarker-led (BLC) or standard care (SC) groups. In the former, test results are revealed and recruits will have their anti-rejection drugs changed to a regime of prednisone, tacrolimus and MMF, each already licensed for use in transplant recipients. We have evidence that this regime is effective at preventing graft dysfunction and expect this to feed through to improvements in survival. In the SC group, screening results are double blinded and recruits will remain on their current therapies. In those without antibodies, recruits will be randomised to either blinded or unblinded screening and remain on standard treatment. Testing will continue every 8 months; recruits in the unblinded screening group will move into the BLC group if they become antibody positive. The primary outcome is kidney failure rates within 3 years of randomisation in HLA antibody+ recruits, predicted to be approximately 20% in the SC but <10% in the BLC groups. Secondary outcomes include rates of deterioration, the incidence of infections, cancers and diabetes, an analysis of the role of non-adherence with medication, and a scientific study to identify new biomarkers associated with outcomes. A cost analysis will confirm whether the screening programme and treatment protocol can save money by keeping kidney transplants functioning for longer. • From Sept 2013 to Nov 2014 we set up and began recruiting from the 5 original research sites including Guy's Hospital, Manchester Royal Infirmary, Royal London Hospital, St James's University Hospital Leeds, University Hospital Birmingham. • To increase recruitment rates we are now also recruiting from King's College Hospital and University Hospitals Coventry and Warwickshire NHS Trust. • York Hospital will also be joining the study as the 8th research site in December 2014. • To date we have consented 861 participants. • Our recruitment target is 2800 by December 2015 |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | currently recruiting |
| URL | http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13990 |
| Title | PoWAR Randomised controlled trial of antibiotics in laparoscopic donor nephrectomy |
| Description | pan-London study which is funded by the NIHR and is on the CLRN portfolio. The study will examine the role of antibiotics in these patients as well as studying wound healing and factors affecting this, and is the first such study worldwide. The trial includes a novel sub-study to assess the use of ultrasound in measuring wound healing. The project has ethical approval and recruitment is about to start. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The project has ethical approval and recruitment is about to start. |
| URL | http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=13238 |
| Title | Pyschosocial aspects of living donation |
| Description | study, which aims to develop mechanisms to predict poor psychosocial outcomes after living donation, and to assess the extent of psychosocial benefit after donation. The study has been developed in collaboration with Professor John Weinmann from the Department of Psychology at Guys Hospital. The project includes the first study in the UK of those undertaking non-directed (altruistic) donation, which is being carried out in collaboration with NHS Blood and Transplant. Recruitment is underway. |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | Recruitment is underway. |
| Title | ReMIND Rituximab in Renal Transplantation |
| Description | large multicentre, investigator led randomised controlled trial of rituximab for induction in renal transplantation. This study will assess the safety and efficacy of using B cell depletion to permit minimisation of immunosuppression. In addition, the effects of B cell depletion on T cell responses and B cell reconstitution will be studied. Professor Giovanna Lombardi from the MRC Centre for Transplantation is collaborating on this aspect of the study, preliminary work has been carried out using samples from patients undergoing blood group incompatible transplantation. The study has been funded, is on the NIHR CLRN portfolio and has ethical and MHRA approval. Recruitment has now started, with 7 centres across the UK participating. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2010 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The study has been funded, is on the NIHR CLRN portfolio and has ethical and MHRA approval. Recruitment has now started, with 7 centres across the UK participating. |
| URL | http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=9154 |
| Title | Rifaximin |
| Description | A placebo-controlled double-blind randomised trial to investigate the efficacy of Rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy. Patients with liver cirrhosis are particularly at risk of getting bacterial infections, and these can lead to complications such as hepatic encephalopathy (HE). This affects brain function and can cause symptoms that range from changes in personality to altered memory, concentration, or even loss of consciousness, affecting quality of life in a major way and often leading to hospital admission, and sometimes even the need for liver transplantation. This study aims to assess an antibiotic called Rifaximin to measure how it affects those processes that are thought to be important in the development of HE. These include the immune function and changes in gut bacteria and overall gut 'leakiness'. The trial is funded by Norgine UK Ltd and will be recruiting from mid-2014 for 12 months |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | 58% relative reduction in the risk of breakthrough episodes of overt hepatic encephalopathy over 6 months (Hazard ratio 0.42; p<0.001). Thus the numbers needed to treat • A 50% relative reduction in the risk of hospitalisations caused by HE over 6 months (Hazard ratio 0.50; p=0.01). Thus the numbers needed to treat |
| URL | http://www.norgine.com/get-file/files/press%20releases/2013/UK%20TARGAXAN%20Press%20Release_1.pdf |
| Title | RituxiCAN-C4 trial |
| Description | Purpose of clinical trial; Evaluate the effectiveness of rituximab in C4d+ CAN Primary objective; To determine whether anti-CD20 therapy can stabilize or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed. Secondary objective (s); •To compare patient and graft survival between control and rituximab-treated groups •To evaluate the adverse effect profile of rituximab in this group •To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab •To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2007 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | currently recruiting |
| URL | http://clinicaltrials.gov/show/NCT00476164 |
| Title | Safety & Efficacy of Eculizumab to Prevent AMR in Deceased Donor Kidney Transplant Recipients Requiring Desensitization |
| Description | two new multicentre studies of eculizumab in highly sensitized patients; these examine the effects of complement inhibition as prophylaxis against early antibody mediated rejection, and both are ground-breaking studies of a new therapy. We are also carrying out a sub-study using samples from participants across the world to examine the effects of the drug on complement activation pathways. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | I am principal investigator for two new multicentre studies of eculizumab in highly sensitized patients; these examine the effects of complement inhibition as prophylaxis against early antibody mediated rejection, and both are ground-breaking studies of a new therapy. We are also carrying out a sub-study using samples from participants across the world to examine the effects of the drug on complement activation pathways. |
| URL | http://clinicaltrials.gov/show/NCT01399593 |
| Title | Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization |
| Description | I am principal investigator for two new multicentre studies of eculizumab in highly sensitized patients; these examine the effects of complement inhibition as prophylaxis against early antibody mediated rejection, and both are ground-breaking studies of a new therapy. We are also carrying out a sub-study using samples from participants across the world to examine the effects of the drug on complement activation pathways. Recruitment is now closed. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | N/A |
| URL | http://www.controlled-trials.com/ISRCTN45444578/ |
| Title | ThRIL-liver transplant patients |
| Description | Cell therapy in liver transplant patients. Cell product in development in the GMP facility. Financed by the MRC. 7 patients have been recruited and for 1 the cells are expanding in the GMP facility and the cells will be injected in 3 months. We plan to open three more sites to increase the number of patients recruited. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Immunosuppressive withdraw in liver transplant patients and indefinite survival of the transplant. |
| URL | https://clinicaltrials.gov/show/NCT02166177 |
| Title | The ONE Study: A unified approach to evaluating cellular immunotherapy in solid organ transplantation |
| Description | Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. For this reason new transplant research should concentrate on early strategies that support long-term immunological acceptance of transplants, allowing for at least a reduction in the use of general immunosuppression. Conditioning the immune response of solid organ transplant recipients towards allograft acceptance using cell-based therapies is now becoming technically feasible and clinically promising. The central focus of the ONE Study cooperative work programme is to: produce and manufacture distinct populations of haematopoietic immunoregulatory cells comparatively study the immunosuppressive characteristics of these regulatory cell types test these cell therapy products side-by-side in a clinical trial in living donor renal transplant recipient https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004301-24 2014 Recruitment update: 12 patients need to be recruited (between KCL and Oxford). Oxford has recruited 5 (4 have already received the cells and for 1 the cell preparation failed) and KCL have recruited 3 (for 1 the cells are expanding in the GMP and they will be injected in January). 4 more patients need to be recruited between KCL (3) and Oxford (2) |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2010 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | DRKS00006366 |
| Impact | recruiting |
| URL | http://www.onestudy.org/documents/ONE_STUDY_BROCHURE_2013.pdf |
| Title | anti-VISTA therapy for clinical trials in oncology |
| Description | Together with JNJ we are developing anti-VISTA therapy for clinical trials in oncology |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | none |
| Title | immunotherapy for prostate cancer |
| Description | Prostate Cancer Research Centre £2.1 million |
| Type | Therapeutic Intervention - Drug |
| Year Development Stage Completed | 2016 |
| Development Status | Under active development/distribution |
| Impact | Our cytotopically modified agents can kill prostate cancer in a murine model in 73 days without any obvious side effects or collateral damage |
| Title | Almetric |
| Description | Web version of BJUI |
| Type Of Technology | Webtool/Application |
| Year Produced | 2013 |
| Impact | Most read surgical journal on the web, Altmetric top 100 in 2015 |
| Company Name | ImmuNext |
| Description | Discovery of immunoregulatory moecuels for therapy. ImmuNext is dedicated to developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. Dr. Randolph Noelle, our founder, from the Geisel School of Medicine at Dartmouth, has identified a number of immuno-modulatory targets and related drug candidates. The lead program is based on VISTA, a novel checkpoint regulator in the B7 family. We are located in Lebanon, NH, with a great combination of intellectual stimulation from Dartmouth College and the beauty of rural New England. |
| Year Established | 2009 |
| Impact | Licensed VISTA to JNJ (Janseen Biothech) for cancer immunotherapy |
| Website | http://immunext.com |
| Company Name | QUELL THERAPEUTICS LIMITED |
| Description | Generation of regulatory T cells to regulate the immune response in transplant rejection |
| Year Established | 2019 |
| Impact | Work in progress |
| Website | https://quell-tx.com |
| Company Name | QUELL THERAPEUTICS LIMITED |
| Description | Quell is a spin-off whose objective is to develop engineered regulatory T cells to treat transplant rejection, autoimmunity and inflammatory diseases. Quell was founded in March 2019 in partnership with scientists from King's College London, University College London and Hannover Medical School. Quell was founded with initial series A financing, led by Syncona Ltd who committed £34M with a further £1M contributed by UCL Technology Fund. |
| Year Established | 2019 |
| Impact | Quell currently has 12 FTE scientific posts within an overall staff of 22 people. |
| Website | https://quell-tx.com |
| Description | 1 lecture in Science week Instituto Canada Blanch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | http://www.sruk.org.uk/documents/press-releases/130430-SRUKScienceWeek-Eng.pdf |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://monix.a.tripod.com/spanish_school_london/welcome.html |
| Description | Academy of Medical Sciences and Association of Physicians |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | To bring together world class speakers and leading industry experts from across European Pharma, Biotech and Academic sectors to share, discuss, collaborate and innovate. Latest scientific breakthroughs, target validation studies, innovative technologies, and new therapeutics will be discussed. |
| Year(s) Of Engagement Activity | 2017 |
| Description | American Association of Asthma, Allergy and Immunology Annual Conference, Houston, Texas |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientiiucfuture collaborations |
| Year(s) Of Engagement Activity | 2015 |
| Description | American Association of Immunologists, Annual meeting in New Orleans, LA, USA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientific future collaborations. |
| Year(s) Of Engagement Activity | 2015 |
| Description | American Urological Association |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | ? |
| Year(s) Of Engagement Activity | 2014,2015,2016 |
| Description | American Urological Association 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This is the largest urology conference in the world |
| Year(s) Of Engagement Activity | 2017 |
| Description | Association of Physicians of G B & Ireland Annual meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Networking with academic colleagues Progressed discussions with Head of Biochemistry at Cambridge |
| Year(s) Of Engagement Activity | Pre-2006,2006,2007,2008,2009,2010,2011,2012,2013,2014 |
| Description | Athena Swan Away Day 2014 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | We hosted a Divisional away afternoon; half of the meeting was dedicated to Athena Swan and the other half was dedicated to increasing our teaching activities. We had talks followed by team working sessions; each team was given a specific question to focus on and answer. All the answers were fedback and discussed at the end of the session. The afternoon concluded with a networking & social reception. This informed our strategy and action plan for Athena Swan. We are no w preparing to submit an application for Silver Award and have a local self-assessment team that meets regularly and that is chaired by a Female Senior Clinical Lecturer. We have changed some of our practices and have put actions in place that support the Athena Swan Charter and our peers. Some of those actions include monthly lunch time seminars dedicated to our postdoctoral researchers; decision making meetings rotate day and time and always occur during core hours; our division has a dedicated Athena Swan "our women in science" section- the MRC Centre website links to this. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.kcl.ac.uk/lsm/research/divisions/timb/athena/casestudiestimb.aspx |
| Description | Away Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | We formulated a workshop programme for the renewal phase of the Centre. Holding a series of interdisciplinary workshops with specific academic and translational goals. |
| Year(s) Of Engagement Activity | 2012 |
| Description | BBC R4 - Recorded broadcast with Dame Joan Bakewell 'Inside the Ethics Committee' |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | BBC R4 - Recorded broadcast with Dame Joan Bakewell on Transplantation for the BBC R4 series 'Inside the Ethics Committee' In Inside the Ethics Committee, Joan Bakewell presents real life medical cases to a panel of experts, each of whom sits on clinical ethics committees around the UK. By examining testimonies from patients, relatives and clinicians, the panel will weigh up the ethical dilemmas involved and make their recommendations about the case at the end of the programme. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.bbc.co.uk/podcasts/series/iec; http://www.bbc.co.uk/programmes/b007xbtd |
| Description | BM1305 COST meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A discussion on how the last grant period has been |
| Year(s) Of Engagement Activity | 2017 |
| Description | BTS Harrogate 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker and Medawar Medal Interlocuter, British transplant Society Congress 2017, Harrogate UK Talk deliverd on Fucose: a promising new therapeutic target in kidney transplants? providing opportunity for discussion and feedback |
| Year(s) Of Engagement Activity | 2017 |
| Description | British GQ Special Report: A delicate operation |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Type Of Presentation | Paper Presentation |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | The Centre's Professor Prokar Dasgupta stars in this autumn's British GQ Special Report: A delicate operation, which tells the story of when one of the world's leading prostate surgeons, Professor Roger Kirby, himself underwent a radical prostatectomy following a diagnosis of prostate cancer in September last year. Professor Dasgupta, who learned robotics alongside Kirby in the US and has helped pioneer robotic urological surgical techniques, led the team who performed the 90 minute operation with the hi-tech da Vinci robot, one of 30 such instruments in Britain and the gold-standard treatment for a number of cancers. The article, as well as covering Kirby's diagnosis and treatment, explores the highly controversial PSA (prostate-specific antigen) screening and the arguments for and against surgical intervention, "a debate peppered with issues of priorities, medical expertise, money and robotic science". The full article can be found in the September 2013 issue of British Gentlemen's Quarterly, also available on iPad. The article, as well as covering Kirby's diagnosis and treatment, explores the highly controversial PSA (prostate-specific antigen) screening and the arguments for and against surgical intervention, "a debate peppered with issues of priorities, medical expertise, money and robotic science". |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://transplantation.kcl.ac.uk/sections/site/news |
| Description | British Society of Histocompatibility and Immunogenetics (BSHI) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Talks and discussions on new advances in both technology and therapy for transplantation |
| Year(s) Of Engagement Activity | 2017 |
| Description | Cell Symposia Conference - Cancer Inflammation and Immunity |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference - 200 people |
| Year(s) Of Engagement Activity | 2017 |
| Description | Cellular and Molecular mechanisms and new therapeutic concepts in translation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A 2 day symposium |
| Year(s) Of Engagement Activity | 2017 |
| Description | Claire Sharpe gender equality in labs - huffington post |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Blog post about the current and future of gender equality in research labs |
| Year(s) Of Engagement Activity | 2017 |
| Description | Co-organiser and chair person at Humanised Mouse Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Co-organised and chaired a workshop humanised mouse symposium |
| Year(s) Of Engagement Activity | 2017 |
| Description | Cold Spring Harbor Laboratory Conference 'Fundamental Immunology & Its Therapeutic Potential', Cold Spring Harbor, NY, USA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientific future collaborations as well as 3 invitations to write reviews for (high impact) journals. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Committee Chair Member- COST, Galway |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chair person and participant to discussions at COST, Galway meeting |
| Year(s) Of Engagement Activity | 2016 |
| Description | Committee Member- ONE Study, Regensberg |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Participant to discussions as a member of the committee and working group |
| Year(s) Of Engagement Activity | 2016 |
| Description | Complement UK training meeting - Complement for practitioners |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Training in Complement including mechanisms, bio markers and therapeutics, for medical practitioners and clinical laboratory scientists and industry. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Debate at National British Society for Histocompatibility and Immunogenetics meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker at Keynote debate |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.bshi.org.uk/html/bshi_2017.html |
| Description | Diseases Plenary Session at ISCT 2017 London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | so that the broad membership of ISCT can attend the Plenary Sessions for education in areas in which they are not experts and then attendees with specific interest in a field can attend the Plenary Breakout sessions which relate to their specific fields of interest for a more in depth presentation of the research. ISo that invited speakers have a greater opportunity to present their work in a single conference. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Documentary - monoclonal antibodies |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | contribution by interview to film documentary on the history of Monoclonal Antibodies to be shown in cinemas and available online |
| Year(s) Of Engagement Activity | 2017 |
| Description | ELRIG Research and Innovation conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Regulatory T cell therapy in organ transplantation |
| Year(s) Of Engagement Activity | 2017 |
| Description | ERUS |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Live surgery. Best poster award |
| Year(s) Of Engagement Activity | 2014,2015,2016 |
| Description | ESOT 2017 Barcelona |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | An educational experience to a broad audience with discussion |
| Year(s) Of Engagement Activity | 2017 |
| Description | Ericsson-KCL event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Unique collaboration on 5G technology. Packaging advances in surgical science to a lay audience |
| Year(s) Of Engagement Activity | 2016 |
| Description | European Association of Urology |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | - |
| Year(s) Of Engagement Activity | 2014,2015,2016 |
| Description | European Association of Urology Meeting 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference > 1000 delegates |
| Year(s) Of Engagement Activity | 2017 |
| Description | Final ONE meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | mmmmmm |
| Year(s) Of Engagement Activity | 2017 |
| Description | First ERUS International Robotic Curriculum |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Professor Prokar Dasgupta has helped to develop the first ERUS (European Association of Urology Robotic Urology Section) international robotic curriculum. Designed for surgeons specialising in robotic urology, the ERUS Fellowship lasts for 6-12 months and provides a structured training pathway to enable surgeons to perform a robot-assisted prostatectomy independently http://erus2013.com/ Guy's and St Thomas' NHS Foundation Trust is one of 10 participating institutions and the only host-institute in the UK. Professor Dasgupta has mentored one of the first graduating fellows through the initial 3 month pilot study, the first time that a formal curriculum has been tried and tested by participants; the results were presented at this year's ERUS Congress in Stockholm. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.uroweb.org/index.php?id=462%20 |
| Description | Frontiers in Transplantation Course |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | workshop facilitator |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A course for clinicians and scientists interested in translational transplantation research. Attended by more than 80 people in 2014. I was highest rated speaker in 2015 and 2017 Second URL relating to 2013 course: https://www.youtube.com/watch?v=ZlzUAzOj47A Extremely good feedback scores form participants has ensured we will make this an annual event |
| Year(s) Of Engagement Activity | 2011,2012,2013,2014,2015,2016,2017 |
| URL | https://www.youtube.com/watch?v=dRnOEYs9hCQ |
| Description | GAMBIT/Decisions open evening |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Event organised to provide members of the public that had participated the DECISIONS and GAMBIT transplant studies with a chance to learn more about the findings from the research and how the work will help our patients. The event, included a tour of the Medical Research Council Centre for Transplantation at Guy's Hospital, an overview of the key findings from both studies and a research poster presentation and reception. This enabled findings to be shared with patients and investigators felt that being able to meet the patients and explain the processes behind the scenes reaffirmed the importance of our research, and was a fantastic way to round off the work we have achieved together." The feedback received following the event was overwhelmingly positive, one patient commented: "It was interesting to see how the equipment and technology has changed over the years. The evening was an excellent presentation of results. It's so good to have all of this information |
| Year(s) Of Engagement Activity | 2016 |
| Description | ISN Nexus 2016 Berlin |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker and session chair ISN Nexus Symposium Berlin to share results and provoke discussion. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Immunotherapies in transplantation and cancer |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A meeting focused on immunological mechanisms and treatments in transplantation and cancer that are common but have opposite final effects in each of these situations; a given tolerogenic mechanisms need to be fostered in transplantation and inhibited in cancer and viceversa. |
| Year(s) Of Engagement Activity | 2012,2017 |
| Description | International Transplantomics Conference Organiser & Chair |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | 100 attendees; location: Cambridge UK; May 2013; 4th International Conference onTransplantomics and Biomarkers. excellent feedback; Transplantation journal issue pending. |
| Year(s) Of Engagement Activity | 2013 |
| Description | International conferenc on complement therapeutics Rhodes 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker at the 9th International conference on complement therapeutics, Rhodes 2016. Talk give on the Role of Collectin 11 in injury of the newly transplanted kidney providing opportunity for feedback and discussion |
| Year(s) Of Engagement Activity | 2016 |
| Description | Invited speaker, 29th International Congress of The Transplantation Society, Buenos Aires, Argentina. Innate activation and the post-surgery immune response |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker, 29th International Congress of The Transplantation Society, Buenos Aires, Argentina. Innate activation and the post-surgery immune response, especially therapeutic approach in the EMPIRIKAL-2 trial |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://cm.tts2022.org/lectures |
| Description | Key note speaker at a conference- 3rd International Molecular and Immunology & Immunogenetics Congress |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk entitled: "Clinical grade manufacture of Regulatory T cells to promote Transplantation Tolerance: Challenges and Achievements." |
| Year(s) Of Engagement Activity | 2016,2017 |
| Description | Key note speaker at conference- CST-CNTRP-SQT Joint scientific Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave a talk entitled: "The use of Tregs in Kidney Transplantation." |
| Year(s) Of Engagement Activity | 2016 |
| Description | Key note speaker to conference- Club de la Transplantation- Lille, France |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave a talk entitled: "Immunotherapy after TH, ThRIL Trial |
| Year(s) Of Engagement Activity | 2017 |
| Description | Key note speaker- Inaugural UK Regenerative Medicine Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave a talk entitled: " Immunological characterisation of IPS-derived cells." |
| Year(s) Of Engagement Activity | 2016 |
| Description | LMB Alumni Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Saw new state of the art facilities in the new LMB and made contact with several key principal investigators; linked up with colleagues from the past who have made subsequent contributions to science Drawn attention to new programme of work in field of complement at the LMB |
| Year(s) Of Engagement Activity | 2014 |
| Description | Liver cell therapy workshop, warwickshire UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Session Chair at the 4th Liver Cell Therapy Workshop, Warwickshire, UK provoking discussion and debate |
| Year(s) Of Engagement Activity | 2017 |
| Description | London Immunology Group and the British Society for Immunology |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Annual Symposium with debate with panel of invited speakers. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Lymphatics in chronic rejection |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | I was the invited international speaker of a plenary session at the American Transplant Congress. |
| Year(s) Of Engagement Activity | 2019 |
| Description | MRC Centenary Max Perutz Science Writing Award ceremony |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Poster Presentation |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | re-used some of our MRC open day event exhibits: A life without medication; multi-player video game : • "Excellent exhibition. Great use of multimedia and very worthwhile exhibit. A very good way to commemorate the MRC!" • "Really enjoyed layout and presentation of projected images. Great interactive game!" |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.mrc.ac.uk/Newspublications/News/MRC009446 |
| Description | MRC Centenary- Science Museum London Centres Cluster |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | On the 15th and 16th June, volunteers from the Centre took part in the MRC Science Festival at London's Science Museum. Nine London MRC Centres came together to create 'Life: A healthy game of chance and choice', showcasing the latest MRC research. Our volunteers teamed up with Morgan, the organ delivery driver from performance group Non Zero One, to create our stand 'replacement parts', where visitors discovered what happens after a transplant and the research taking place in the Centre, which aims to help patients return to a healthy life. 1,332 visitors attended the festival over the weekend, with 97% reporting the event as "good" or "very good" |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.centenary.mrc.ac.uk/events/science-festival/ |
| Description | MRC Centenary- The Future of Transplantation with Jonathan Dimbleby |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | In the evening, approximately 180 attendees were treated to a debate on The Future of Transplantation, hosted by Jonathan Dimbleby. Following a welcome from the Principal, a distinguished panel from the worlds of science, literature and philosophy engaged in a lively and entertaining discussion exploring topics such as the use of stem cells and its public and political acceptability, and the role of genetic research in transplant science. Panellists were: • Stuart Forbes, Professor of Transplantation and Regenerative Medicine, University of Edinburgh • Sir Robert Lechler, Vice-Principal (Health) and Executive Director of King's Health Partners Academic Health Sciences Centre at King's College, London • Rutger Ploeg, Professor of Transplant Biology and Transplant Surgeon, University of Oxford • Janet Radcliffe Richards, Professor of Practical Philosophy, University of Oxford • Sue Townsend, novelist and kidney transplant recipient • Eleanor Updale, writer, historian and lay member of the UK Donation Ethics Committee Statistics from the Eventbrite registration website show that although a total of 39% of those who attended were employed in the medical or scientific professions, 23% were from other professions and the individual group with the highest representation was students, making up 30% of the audience. This included a class of 30 A-Level students. Of those who attended, approximately half have received a transplant or know someone who has. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://transplantation.kcl.ac.uk/sections/site/education-information |
| Description | MRC Centenary- The Science and Art of Transplantation |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Poster Presentation |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The exhibition, attended by 189 visitors throughout the day, consisted of five multimedia galleries, with volunteers from the Centre on hand throughout the day to speak to visitors about their research. • Pioneers Gallery - interviews from pioneers of science and transplantation, connecting MRC discoveries with the treatment of transplant patients today • Extending the life of the transplant; "Pepper's Ghost" holographic model with kidney perfusion video footage • A life without medication; multi-player video game • Cell Transplantation; plasma information screen focusing on the hepatocyte programme, islet, and bone marrow work • Patient journey; patient wall with stories from 28 transplant recipients and their families. Patients Richard Lane and Lesley Beadle also attended giving visitors the opportunity to hear first-hand about life as a transplant donor or recipient 84 % of those who returned a feedback form reported that the exhibition had improved their understanding of the Medical Research Council and of the work that it has achieved. Further, 81% claimed a better understanding of organ transplantation following the event. • "Excellent exhibition. Great use of multimedia and very worthwhile exhibit. A very good way to commemorate the MRC!" • "It was great! And no jargon so easily understandable" • "Really enjoyed the exhibition and speaking with the researchers especially. The work they are doing is so interesting!" • "Keep up the good work!" • "I appreciated how well the professor explained the research and how encouraging they were" • "Really enjoyed layout and presentation of projected images. Great interactive game!" See text above for statistics and feedback. We have been asked to re-use some of our exhibits (the digital multiplayer interactive game showing transplant tolerance versus rejection) for the Science Museum late series for the MRC Max Perutz Science Writing Award ceremony. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://transplantation.kcl.ac.uk/sections/site/education-information |
| Description | MRC Centre 10th anniversary |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The event consisted of artifacts, art, patient stories, wax models and a professional drama production (The Messenger) reflecting different aspects of our research, patient benefits and ethical issues of organ donation. It included prize presentations following the MRC Festival winners early in the year and for the best scientific images. |
| Year(s) Of Engagement Activity | 2017 |
| Description | MRC Festival, Social Mobility Foundation visit to the MRC Centre |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Potential career seekers in Science visited for a 1 day program about the evolution of clinical trials from bench to bedside entitled "The life cycle of a clinical trial". They met with investigators involved in this work. With coaching from a professional illustrator they created their own art pieces and flow charts depicting the life cycle. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Martin Drage in BBC2's Keeping Britain Alive |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Martin Drage in BBC2's Keeping Britain Alive Mr Martin Drage, Consultant Transplant Surgeon, MRC Centre for Transplantation, starred in episode 2 of BBC series, 'Keeping Britain Alive: The NHS in a day', broadcast on Tuesday 2nd April 21.00 - 22.00 on BBC Two. Filmed on Thursday 18 October 2012 by 100 camera crews across the country, this ground-breaking series explores the breadth of demands that are placed on the NHS in one single day. This episode features a transplant operation in which Alan is donating a kidney to his wife of 27 years Ann. The programme features Mr Drage preparing the patients and performing the possibly life-threatening surgery. The programme will be available to view on BBC iPlayer until 21st May. better understanding of the health care system and organ transplantation; highlights the importance of the work carried out at the MRC Centre for Transplantation. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.bbc.co.uk/programmes/b01rsvxd |
| Description | Member of committee- TWO Study meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | participant of committee and to discussions at this meeting |
| Year(s) Of Engagement Activity | 2017 |
| Description | NIHR BTRU in ODT |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | NIHR BTRU in Organ Donation and Transplantation |
| Year(s) Of Engagement Activity | 2018 |
| Description | NIHR in BTRU in ODT |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | interactive workshop involving academics creating a forum to present and share ideas |
| Year(s) Of Engagement Activity | 2017 |
| Description | National Institutes of Health Immunology Interest Group Seminar Series |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientific future collaborations. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Pankaj chandak - MRC insight |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | MRC insight post about "transforming transplantation" Dr Pankaj Chandak's work with 3D printing to facilitate cmioplex transplantation surgery. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Patient group workshop (LISTEN group Kings College Hospital) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | The LISTEN group is a support group for liver transplant patients at Kings College Hospital. I provide yearly workshops to discuss ongoing research in liver transplantation consisting in a short presentation followed by a debate. |
| Year(s) Of Engagement Activity | 2014,2015,2016,2017 |
| Description | Personally asked as a key note speaker to a conference- AFACRR Management Committee and working group- Belgrade |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave a talk entitled: "Clinical grade manufacture of Regulatory T Cells to promote Transplantation Tolerance: Challenges and Achievements." |
| Year(s) Of Engagement Activity | 2016 |
| Description | Regulation of the immune response in support of hematopoietic progenitor cell and solid organ transplantation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | British Society for Immunology Congress |
| Year(s) Of Engagement Activity | 2017 |
| Description | Response to SKY TV media enquiry on the Human Tissue (Wales) Act 2013 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Response to SKY TV media enquiry on the Human Tissue (Wales) Act 2013 - which received Royal Assent in September 2013. An Act of the National Assembly for Wales to make provision concerning the consent required for the removal, storage and use of human organs and tissue for the purpose of transplantation; and for connected purposes. Passed by the National Assembly for Wales and received the assent of Her Majesty in September 2013. The law will come fully into effect on 1st December 2015. |
| Year(s) Of Engagement Activity | 2013 |
| Description | Seminar - Sir William Dunn School of Pathology |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Interest and further discussions followed Strengthened links in support of application for UKRMP Immunology Stem Cell Hub |
| Year(s) Of Engagement Activity | 2014 |
| Description | Session Organiser for BSI 2013 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | None as yet - Meeting occurring 2-5 December 2013 |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.bsicongress.com/ |
| Description | Social Mobility Foundation Inernship programme |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | The Social Mobility Foundation is organising Internship Programmes every year and the MRC Centre offered to be involved, quote from one of our interns "I just wanted to say a quick thank you as the internship was very useful as it has undoubtedly heightened my understanding of the career path that I am considering. Not only has it allowed me to expand my knowledge beyond the curriculum but it has also boosted my confidence and interpersonal skills. Thank you very much for such a great opportunity." This student is about to start her final year and pass her A levels and move on to a science higher degree. |
| Year(s) Of Engagement Activity | 2010,2011,2012,2013,2014 |
| URL | http://www.socialmobility.org.uk/ |
| Description | Societe Internationale Urologie 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Large international conference |
| Year(s) Of Engagement Activity | 2017 |
| Description | Steve Sacks - 8th International Conference on Complement Therapeutics, Crete, Greece |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker |
| Year(s) Of Engagement Activity | 2015 |
| Description | Steve Sacks - American Society of Nephrology, San Diego, USA |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker |
| Year(s) Of Engagement Activity | 2015 |
| Description | Steve Sacks - BANFF-CST |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker for the BANFF-CST Joint Scientific Meeting, Vancouver, Canada |
| Year(s) Of Engagement Activity | 2015 |
| Description | Steve Sacks - CEOT Symposium, Phoenix, USA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker |
| Year(s) Of Engagement Activity | 2016 |
| Description | Steve Sacks - Complement UK Symposium and Training Course, Cambridge, UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Co-organiser and speaker |
| Year(s) Of Engagement Activity | 2015 |
| Description | Steve Sacks - Joint British Transplantation Society and Nederlandse Tranplantatie Vereniging Congress, Bournemouth, UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker. Talk title: ' A new signal for cell death in post-ischaemic injury' |
| Year(s) Of Engagement Activity | 2015 |
| Description | Steve Sacks - Royal Society |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker, Royal Society Meeting on Complement: driver of inflammation and therapeutic target in diverse disease, Buckinghamshire, UK |
| Year(s) Of Engagement Activity | 2015 |
| Description | The 2016 Immunosuppression Summit |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk title: Targeting donor rather than recipient cells to prevent rejection of transplanted organs. |
| Year(s) Of Engagement Activity | 2016 |
| Description | The Organ Lottery: why access to more and better transplants matters |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Questions and answers in the world of organ donation are far from black and white. Yet for those not immersed in this world daily who are thrust into situations they are unprepared for when a loved one falls ill, it's almost impossible to see medical decisions from every angle and understand the possible benefits of transplant research. In this interactive debate, we will explore multiple points of view, considerations and medical opinions that come together at this crucial point to make a life or death decision. Jonathan Dimbleby and a panel of experts will discuss what lies behind a transplant decision at an exciting debate organised by the Centre's Dr Antonia Cronin and King's Policy Institute. The event takes place on 10th December at 6pm at Wellcome Collection, 183 Euston Road, NW1 2BE. It is free to attend but entry is ticketed with limited availability Event not yet taken place |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.eventbrite.co.uk/e/the-organ-lottery-why-access-to-more-and-better-transplants-matters-re... |
| Description | Therapeutic Tolerance Workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | informal networking opportunity with discussion |
| Year(s) Of Engagement Activity | 2017 |
| Description | Transcampus Transplantation programme with Dresden |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Transcampus meeting between the MRC Centre for Transplantation and the DFG Centre for Xenotransplantation based in Munich. Involved research presentations, planning and follow up visits. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Transplantation morning 19 May 2015 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | The biomarker team had an informal talk about biomarker research mostly with local patients and staff. |
| Year(s) Of Engagement Activity | 2015 |
| Description | UCB Seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Collaboration project |
| Year(s) Of Engagement Activity | 2017 |
| Description | UK Humanised Mouse Symposium |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | A working group |
| Year(s) Of Engagement Activity | 2018 |
| Description | UK Kidney Week 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | an update on therapies in renal transplantation |
| Year(s) Of Engagement Activity | 2017 |
| Description | UKRMP 2 Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | A working group |
| Year(s) Of Engagement Activity | 2018 |
| Description | UKRMP NHSBT joint workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | forum to plan future strategy and collaborations in the field |
| Year(s) Of Engagement Activity | 2017 |
| Description | USANZ, Australia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Global prize |
| Year(s) Of Engagement Activity | 2014,2015,2016 |
| Description | Urological Society of India |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 2000 attendees came to my session on systematic reviews and critical appraisal |
| Year(s) Of Engagement Activity | 2016 |
| Description | Visit of MEP and MP |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | One MEP and one MP attended to receive information about the involvement of King's in EU funding scheme. They will report the success of Kings in gaining EU funding at parliamentary and european levels. |
| Year(s) Of Engagement Activity | 2013 |
| Description | clinical trials day 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Leaflet and attendance at clinical trials day organised by the GSTT NHS trust in hospital foyer - describing trials based within the centre - stall open to general public. |
| Year(s) Of Engagement Activity | 2016 |
| Description | key note speaker to conference- Instituo de Medicina Molecular- Lisbon |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave a talk entitled: "Approaching clinical Transplantation tolerance." |
| Year(s) Of Engagement Activity | 2017 |
| Description | recorded lecture - Complement and organ transplantation |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | REcorded talk for HS talks on "Complement and Organ Transplants" available online for academic and other subscribers. |
| Year(s) Of Engagement Activity | 2017 |
| Description | workexperience students |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | student spent 1 week in the immunoregulation laboratory doing cell culture and watching other experiments. improved understanding of science- student wants to learn science after her A levels. |
| Year(s) Of Engagement Activity | 2013 |